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ABSTRACT 
 
 The transplantation of allogeneic cells and tissues for the treatment of human 
disease has been a life-saving procedure for many thousands of patients worldwide. 
However, to date, neither solid organ transplantation nor bone marrow transplantation 
have reached their full clinical potential. Significant limitations to the advancement of 
clinical transplantation stem from our current inability to prevent the rejection of 
allogeneic tissues by the immune system of the host. Similarly, in patients that receive 
allogeneic bone marrow transplants, we cannot permanently prevent the engrafted 
immune system from mounting a response against the patient. This problem, termed graft 
versus host disease is the most prevalent cause of morbidity and mortality in recipients of 
allogeneic bone marrow transplants. 
  Clinically, we rely on lifelong immunosuppression to prolong survival of 
allogeneic tissues within the host. Our currently available therapeutics burden patients 
with side-effects that range from being unpleasant to life-threatening, while in most cases 
offering only a temporary solution to the problem of alloimmunity. Efforts are underway 
to develop protocols and therapeutics that more effectively prevent the pathology 
associated with alloimmunity. To minimize patient risk, extensive pre-clinical studies in 
laboratory animals are conducted to predict clinical responses. In the case of 
immunologic studies, many of these pre-clinical studies are carried out in murine models. 
Unfortunately, studies of murine immunity often do not predict outcomes in the clinic. 
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One approach to overcome this limitation is the development of a small animal model of 
the human immune system. 
 In this dissertation, we hypothesized that NOD-scid IL2rγnull mice engrafted with 
human peripheral blood mononuclear cells (PBMC), termed the hu-PBMC-NOD-scid 
IL2rγnull model, would provide a model that more accurately reflects human immunity in 
vivo than other models currently available. To investigate this possibility, we first 
investigated whether NOD-scid IL2rγnull mice were able to support the engraftment of 
human PBMC. We found that NOD-scid IL2rγnull mice engraft with human PBMC at 
much higher levels then the previous gold standard model, the NOD-scid mouse. We then 
investigated the kinetics of human cell engraftment, determined the optimal cell dose, and 
defined the influence of injection route on engraftment levels. Even at low PBMC input, 
NOD-scid IL2rγnull mice reproducibly support high levels of human PBMC engraftment. 
In contrast to previous stocks of immunodeficient mice, we observed low intra- and inter-
donor variability of engraftment.  
 We next hypothesized that the human PBMC engrafted in NOD-scid IL2rγnull 
mice were functional and would reject transplanted allogeneic human tissues. To test this, 
human islets were transplanted into the spleen of chemically diabetic NOD-scid IL2rγnull 
mice with or without intravenous injection of HLA-mismatched human PBMC. In the 
absence of allogeneic PBMC, the human islets were able to restore and maintain 
normoglycemia. In contrast, human islet grafts were completely rejected following 
injection of HLA-mismatched human PBMC as evidenced by return to hyperglycemia 
and loss of human C-peptide in the circulation. Thus, PBMC engrafted NOD-scid 
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IL2rγnull mice are able to provide an in vivo model of a functional human immune system 
and of human islet allograft rejection.  
 The enhanced ability of NOD-scid IL2rγnull mice to support human cell 
engraftment gave rise to the possibility of creating a model of graft versus host disease 
mediated by a human immune system. To investigate this possibility, human PBMC were 
injected via the tail vein into lightly irradiated NOD-scid IL2rγnull mice. We found that in 
contrast to previous models of GVHD using human PBMC-injected immunodeficient 
mice, these mice consistently (100%) developed GVHD following injection of as few as 
5x106 PBMC, regardless of the PBMC donor used. We then tested the contribution of 
host MHC in the development of GVHD in this model. As in the human disease, the 
development of GVHD was highly dependent on host expression of MHC class I and 
class II molecules. 
 To begin to evaluate the extent to which the PBMC-engrafted NOD-scid IL2rγnull 
humanized mouse model of GVHD represents the clinical disease, we tested the ability of 
a therapeutic in clinical trials to modulate GVHD in these mice. In agreement with the 
clinical experience, we found that interrupting the TNFα signaling cascade with 
etanercept delayed the onset and severity of disease in this model.  
In summary, we conclude that humanized NOD-scid IL2rγnull mice represent an important 
surrogate for investigating in vivo mechanisms of both human islet allograft rejection and 
graft versus host disease. 
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CHAPTER I: INTRODUCTION TO TRANSPLANTATION 
A Brief History of Transplantation  
Transplantation in Antiquity 
 The idea of transplanting tissues in order to treat a specific condition has a very 
long history. The Susruta Samhita, an ancient manuscript written by the Indian surgeon 
Susruta describes a procedure for using a skin flap from the forehead of a patient to repair 
the deformity caused by amputation of the nose (1). This document, written sometime 
between 1000 to 500 B.C. by the “Father of Surgery”, is the earliest existing 
manifestation of the love humanity has for the use of surgical techniques to promote 
medical wellness. Gasparo Tagliacozzi, a 16th century Italian surgeon, adopted Susruta’s 
techniques in rhinoplasty. While he had success with transplanting tissues from one place 
to another on the same individual, referred to as an autograft, transplanting tissues from 
one person to another, referred to an as allograft, were repeatedly unsuccessful. In his 
1596 work De Curtorum Chirurgia per Insitionem, he attributed the failure of allografts 
to the "force and power of individuality" (2). Over the centuries between the lifetimes of 
these two scientists’ and ours, discoveries in the fields of transplantation and 
immunology have had monumental impacts on Medicine as it is practiced today.  
Benchmarks in transplantation 
 Since Susruta’s time, the investigations into transplanting tissues from one animal 
to another of the same species (allotransplantation) or from one species to another 
(xenotransplantation) have resulted in numerous profound discoveries. Many of the 
scientists responsible for these studies have been awarded a Nobel Prize. Indeed, 
  
2 
transplantation immunology and clinical transplantation have led to more Nobel Prizes 
than any other field of Medicine (3). Together, the works of these great scientists have 
been responsible for developing techniques that have saved many thousands of lives.  
 One of the pioneers in developing surgical techniques that are still used in modern 
day transplantation was this French surgeon Alexis Carrel (reviewed in 3). Carrel 
perfected the technique for suturing blood vessels together, without which solid organ 
transplants (and many other surgical procedures) are not possible. Using the techniques 
he developed, Carrel and Charles Claude Guthrie carried out a series of experiments in 
which Carrel observed that a kidney transplanted into a non-biological site in the same 
animal from which it was harvested would remain functional for the lifetime of the 
animal (3,4). However, if an organ harvested from one animal was transplanted into 
another animal of the same species, the organ failed. From this observation, Dr. Carrel 
concluded that animals had “biological incompatibility”, and the idea of an immunologic 
basis for graft failure was borne (3). Dr. Carrel was awarded the 1912 Nobel Prize in 
Medicine for his contributions to vascular surgery and transplantation. Despite the 
integral role he played in the works, Dr. Guthrie was not named in this award, reportedly 
because of some very controversial head transplants he had attempted (5).  
 Another pioneer in transplantation was Sir Peter Medawar, sometimes referred to 
as the “father of transplant immunology”. Medawar became interested in ways to 
improve the outcome of skin grafts during World War II when he was asked to 
“investigate why it is that skin taken from one human being will not form a permanent 
graft on the skin of another person” (6). In studies performed in rabbits (7) and humans 
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(8), Medawar found that skin grafts between two non-identical members of the same 
species (called homografts or allografts) are rejected. He and his colleagues also 
recognized that an animal that receives a second graft from the same donor will reject the 
new graft more quickly (second-set rejection) than the first graft (first-set rejection), a 
process referred to as the amnestic response (9,10). His results led him to be the first to 
report that organ rejection was an immunologic phenomenon (7,8,11) For his many 
contributions to the field of transplantation, Peter Medawar shared the 1960 Nobel Prize 
in Medicine with Sir Frank Macfarlane Burnet, a major contributor to the clonal selection 
theory of lymphocytes.  
The concept of Tolerance 
 In his 1960 Nobel Lecture, Peter Medawar stated that “Immunological tolerance 
may be described as a state of indifference or non-reactivity towards a substance that 
would normally be expected to excite an immunological response” (6). The observation 
that led him to this statement began with a report by Ray Owen describing the finding 
that non-identical twin cattle that shared a placenta would not reject skin grafts from one 
another, but could still reject skin from other cattle (12). These researchers reasoned that 
the sharing of blood supply in utero resulted in the deletion of lymphocytes that were 
reactive to the antigens expressed by the fraternal twin through the process of negative 
selection. Medawar took this observation one step further, hypothesizing that exposure to 
“non-self” cells early in development would lead to tolerance to the source of those cells. 
Conversely, exposure to non-self cells later in development would result in sensitization 
to that antigen. He published this description of immunological tolerance in 1953 (12,13).  
  
4 
 The ability to experimentally induce immunological tolerance early in life had 
been demonstrated as early as 1912. There were reports from the budding field of cancer 
biology that Rous sarcoma cells could be grown in duck or chicken embryos. The 
addition of lymphoid cells isolated from adult chickens, in which the sarcoma cells could 
not grow, caused the sarcoma cells to be destroyed (11). In 1936 Traub made similar 
observations regarding the persistence of LCMV infection following in utero or perinatal 
inoculation, and the immunological clearance of the same virus in adults (11). The works 
of Murphy, Traub and Medawar demonstrated that the barriers of transplantation between 
non-identical subjects could indeed be broken and a state of immune tolerance of donor 
tissues could be induced.  
Immunology of Graft rejection 
Discovery of MHC 
 Dr. Clarence Cook Little, the founder of the Jackson Laboratory in Bar Harbor, 
Maine, discovered that the “susceptibility and resistance to the rejection of tissues are 
influenced by multiple genes showing Mendelian inheritance” (14,15). Following up on 
Little’s work, another pioneer in transplant immunology, George Davis Snell, identified 
the murine histocompatibility locus (H2) as the major genetic determinant of rejection in 
mouse transplantation models (16). Using congenic mice, animals that differ only at 
small defined intervals of the genome, Snell discovered each of four mouse strains tested 
expressed a different allele at the H2 locus. Homologous loci, known as the Major 
Histocompatibility Complex (MHC) were soon discovered in other species. This work 
was the basis of his sharing the 1980 Nobel Prize in Physiology or Medicine with Baruj 
  
5 
Benacerraf, who showed that genetic factors related to the H-antigens were responsible 
for interactions between immune cells, and consequently determined the strength of the 
immune response, and Jean Dausset who discovered H-antigens in humans (HLA). In his 
Nobel Lecture, Snell stated 
Genes competent to play this role in the appropriate experimental or 
surgical context are called histocompatibility or H genes. An influence on 
transplants probably is entirely irrelevant to the true function of such 
genes, but the influence does give the geneticist a handle by which to study 
them. It was by this route that, over a period of a good many years, I 
became involved first in immunogenetics and then in the new and 
fascinating area of cellular immunity (14).  
 A series of landmark studies by Doherty and Zinkernagel gave functional 
significance to Snell’s findings. These researchers found that the targeted in vitro killing 
of lymphocytic choriomeningitis virus (LCMV) infected cells by T-lymphocytes required 
the effector cells and target cells to share expression of at least one H2 locus, called a 
haplotype (17). This demonstration that there was specificity for not only the peptide 
antigen but for the context in which it was presented earned Doherty and Zinkernagel the 
1996 Nobel Prize in Medicine. This knowledge that T-lymphocytes recognize only 
peptide complexed with proteins of the H2 region (later called major histocompatability 
complex, or MHC) began to answer other outstanding questions in the transplantation 
field.  
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Alloreactivity 
 Ten years prior to Doherty and Zinkernagel’s discovery of the requirement for 
peptide to be presented in the context of self-MHC, Darcy Wilson and colleagues 
published a series of papers describing the outcome of mixed lymphocyte reaction (MLR) 
studies utilizing cells isolated from different strains of rats. These studies demonstrated 
that in culture, the “small lymphocytes” from one strain of rat proliferated in response to 
stimulation with cells from a second, genetically distinct strain of rat (allogeneic) but not 
in response to stimulation with cells from a genetically identical rat (syngeneic) (18-20). 
Combined with the elucidation of the biological function of MHC, these studies began 
our understanding of the mechanism of alloreactivity. 
 Alloreactive T lymphocytes, or cells reactive against non-self MHC, are thought 
to be generated through a combination of mechanisms. The first mechanism involves 
polymorphisms in the MHC locus. There is great genetic diversity within the MHC 
regions between members of a species, with as much as 5-10% genetic variability 
between alleles. During thymic development, T lymphocytes bearing T-cell receptors that 
do not react with self MHC/peptide undergo deletion by neglect, while T lymphocytes 
bearing T-cell receptors (TCR) that react too strongly with MHC/peptide will be deleted. 
As the remaining thymocytes by default all react with low affinity to self-MHC/peptide 
complex, some proportion of these cells will react with allogeneic MHC (21).  
 The second mechanism thought to contribute to the generation of alloreactive T-
cells is the degeneracy of the TCR. The ability of a single TCR to recognize multiple 
different peptide/MHC complexes, referred to as the degenerate nature of TCR, has been 
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well documented (22). The consequence of this phenomenon is the higher than expected 
proportion (estimated from 0.1-10%) of cells that recognize allogeneic MHC (23,24) 
compared to the 0.001% of T-lymphocytes that react to a given peptide/self-MHC 
complex (25,26). With the presence of such high numbers of alloreactive lymphocytes it 
is not surprising that the rejection of allogeneic grafts is so robust. 
Mechanisms of Graft Rejection 
 The rejection of allografts can be mediated by both humoral immunity 
(hyperacute rejection) and by cellular immunity (acute and chronic rejection). Although 
each type of rejection occurs by different mechanisms and with different kinetics, all 
three mechanisms must be averted for the transplant recipient to receive the full benefits 
of the organ or tissues they are receiving. 
 By far the fastest form of rejection of allogeneic tissues occurs via the humoral, or 
hyperacute rejection. The first recognized cause of hyperacute rejection was 
transplantation across mismatches in the ABO blood group antigens (11,27). These 
glycoproteins were discovered by Karl Landsteiner in 1902, for which he shared the 1930 
Nobel Prize in Physiology or Medicine. The glycoprotein in each group (A, B or O) 
displays slight differences in the attached sugar moiety. In hyperacute rejection, 
preformed antibodies exist in the host that recognize the ABO glycoproteins of the 
mismatched donor. These antibodies are thought to exist due to prior sensitization of the 
host to the donor tissues or due to crossreacivity with antigens from colonizing bacteria 
(28). Because the ABO glycoproteins are expressed on endothelial cells, these antibodies 
will bind to the vasculature of a mismatched organ, causing blood clots that block organ 
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perfusion. Hyperacute rejection can occur due to antigens other than ABO glycoproteins, 
as well. For example, a patient who has had multiple blood transfusions may have been 
sensitized to an HLA molecule shared between prior and current donors. Due to rapid 
testing techniques routinely performed prior to transplantation today, this method of 
rejection is not often seen.  
 The remaining types of cellular rejection, both acute and chronic, are primarily 
mediated by alloreactive T-lymphocytes. There are two mechanisms involved in cellular 
rejection. In the first mechanism, the recipient’s T cells can recognize the donor MHC 
directly, aptly named direct antigen presentation. In the second mechanism, donor MHC 
molecules can be processed by host antigen presenting cells (APC) (29), and the resulting 
peptides can then be presented by host APC, a process termed indirect antigen 
presentation. Experiments evaluating the percentage of alloreactive cells that recognize 
intact allo-MHC directly versus recognizing the processed peptides of the indirect 
pathway suggest that as high as 90% of allospecific cells are utilizing the direct pathway 
(30). Both direct and indirect pathways of allorecognition are thought to play a role in the 
alloimmune response (29).  
 It has been suggested that acute and chronic rejection are linked to differences 
between the direct and indirect pathways of allorecognition (31,32). Acute rejection 
generally begins in the first weeks after transplantation of an allograft. The large 
proportion of recipient T cells that will react with allogeneic MHC (23,24,30,33) without 
the requirement for antigen processing makes the direct pathway of alloantigen 
presentation an attractive possible mechanism for the acute rejection of allogeneic tissues. 
  
9 
Consistent with this hypothesis, it has been shown in some human recipients of 
allogeneic heart transplants that the numbers of T lymphocytes that can directly recognize 
the MHC of their donor tissues decreases over time (34). This may be explained by the 
depletion of donor APC by the recipients immune system over time (31,32). Conversely, 
indirect presentation of alloantigen would not depend on the presence of donor APCs, as 
the donor-derived alloantigens are processed and presented by host APC. Thus, the 
pathway would remain a viable mechanism for allorecognition over long periods of time. 
This suggests that the indirect pathway of allorecognition is the more important 
mechanism in chronic rejection of allogeneic tissues, which, in the absence of 
“tolerance”, is still the primary barrier to permanent graft survival. There is some clinical 
data in support of this hypothesis. Hornick et al reported finding a higher frequency of 
donor T lymphocytes capable of indirect allorecognition in patients with chronic rejection 
than in those without chronic rejection (35).  
 Although it is interesting to speculate on the relative contributions of direct vs. 
indirect antigen presentation in the rejection process, the relationship these two pathways 
have with acute vs. chronic rejection remains to be fully understood. Regardless, it is 
clear that both of these mechanisms must be targets for therapeutic intervention if 
permanent graft survival is to become a reality. 
Human transplantation 
Background 
 The technical skills required for human organ transplantation were in place long 
before the first successful solid organ transplant between humans occurred in 1954 at the 
  
10 
Peter Bent Brigham Hospital in Boston (36). In that landmark case, Joseph Murray led a 
team of surgeons (including John Merrill, Hartwell Harrison, and David Hume) that 
removed a kidney from a living donor and transplanted it into the donor’s twin brother. It 
was already known at that time that skin grafts between identical twins were readily 
accepted (11). According to John Merrill (37), the patient’s physician, David M. Miller of 
the Public Health Service in Boston, suggested the transplant based on this information. 
This first success provided evidence that the techniques themselves were sound, if only 
better immunosuppression could be achieved.  
Immunosuppression 
 Soon after Medawar’s recognition of rejection as an immunological event, efforts 
to weaken the immune system to promote graft survival began in earnest. The first 
immunosuppressant attempted was cortisone. Early studies using a rabbit model of skin 
graft rejection determined that cortisone successfully prolonged graft survival, albeit for 
only for a few days (10,38). In 1952 some key observations were made by Cannon et al 
regarding the use of cortisone in neonatal transplantation (11,39). The most important 
observation was that cortisone increased the success rate of transplanted skin to over 20% 
without increasing mortality. Further, the grafts remained intact even after the drug was 
discontinued (11). This groundbreaking observation would be the basis for the search for 
more effective means of suppressing the immune function; a quest many researchers are 
still trying to fulfill 50 years later.  
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Cytoablation 
 The use of irradiation to deplete lymphocytes as a means to bring about graft 
survival was described in rabbits by Dempster et al in 1950 (40) and in mice by Main and 
Prehn in 1955 (41). Joseph Murray based his early protocol for kidney transplants 
between non-identical subjects (42) in part on the work of Main and Prehn. This protocol 
utilized lethal, or myloablative, irradiation plus bone marrow transplantation, and was 
implemented in two patients (42). Later protocols utilized sublethal irradiation without 
the addition of bone marrow transplantation in 10 more patients in renal failure (2). 
Unfortunately, 11 of 12 total patients enrolled in these studies died of infection within 
one month (42). The single patient who survived had received a kidney donated from his 
fraternal twin. Perhaps it was thought that because they were related, it would be easier to 
induce tolerance, as this patient received a lower dose of irradiation in the absence of a 
bone marrow transplant, and did remarkably well (11). He experienced two episodes of 
rejection that were treated successfully with low dose irradiation plus cortisone (3,11). He 
then survived with normal renal function for the next twenty years. The successful 
fraternal twin kidney transplant was quickly duplicated in Paris by Hamburger et al using 
the same protocol (43). These two studies were joined shortly thereafter by reported 
successes in kidney transplant between non-related individuals (44).  
The Purine Analogs  
 The anti-metabolite drugs 6-mercaptopurine (6-MP) and azithrioprine were 
originally developed as anti-leukemic agents (45). The discovery of azithioprine, along 
with other drugs, by George Hutchings and Gertrude Elion, earned them the Nobel Prize 
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in Medicine in 1988. These drugs disrupt the de novo pathway of purine synthesis, which 
is the primary pathway used by lymphocytes. (46). A series of experiments by Schwartz 
and Dameshek first demonstrated that these compounds had immunosuppressive 
properties (47), then, along with Meeker (48), demonstrated 6-MP administration delayed 
rejection of skin grafts in rabbits (49). Others soon published similar results with purine 
anti-metabolites in canine models of renal transplantation (50-52). Unfortunately, 95% of 
the animals treated with 6-MP or azithioprine died within 100 days of receiving renal 
transplants (11). This poor statistic held true for human studies as well, as the first three 
renal transplant patients who received 6-MP died (53). A major turning point in the quest 
for superior immunosuppressive agents occurred in 1963, with the report that the less 
toxic azathioprine, in conjunction with high dose prednisone, was able to reverse 
rejection in several kidney transplant recipients (54). Furthermore, many of these patients 
had developed at least a partial immune tolerance to their grafts, and were able to greatly 
reduce their immunosuppressive dose (54). Azathioprine and the newer generation of 
purine biosynthesis inhibitor, mycophenolate mofetil (MMF), are still used clinically 
today. 
Cyclosporine A and Tacrolimus 
 An extract from the fungi Clindrocarpon lucidum and Trichoderma polysporum 
represented a new breakthrough in immunosuppressant drugs for transplantation (11). 
The mechanism of action of this class of drugs is the inhibition of calcineurin, a key 
component of the T cell activation signaling pathway. Cyclosporine was found to 
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suppress immune function in a specific and rapidly reversible way without having the 
bone marrow depression and toxicity issues of earlier drugs (11).  
 The efficacy of cyclosporine was rapidly proven in animal models of heart, 
kidney, pancreas and liver transplantation (55-57). When cyclosporine was used in 
clinical trials (58,59), several serious side effects were discovered. These include toxicity 
to the kidney and pancreatic islets as well as a high incidence of B cell lymphoma. 
(11,60-64). Although the next generation of calcineurin inhibitor, called tacrolimus, 
succeeded in many clinical cases in which cyclosporine had failed (65-67), the side 
effects of the new drug were not much improved (68). Despite the side effects, this class 
of immunosuppressant drugs posed significant improvements over those used previously, 
and are still in use today.  
Inhibitors of mTOR 
 The mammalian target of rapamycin (mTOR) is an important regulator of 
lymphocyte progression into the cell cycle following signaling through the IL-2 receptor 
(69). The mTOR inhibitors, sirolimus (rapamycin) and everolimus, prevent the 
proliferative response of lymphocytes following stimulation (46), and therefore cripple 
the adaptive immune response to the allogeneic target. Like the other immunosuppressive 
agents, adverse effects have been reported, including anemia, leukopenia and lymphoid 
malignancy (70).  
Lymphocyte Specific Immunotherapy 
 Paul Ehrlich, the recipient of the1908 Nobel Prize for Medicine, coined the term 
“magic bullet” in reference to a compound that would selectively target a specific 
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pathogen and destroy it without damaging the host tissue. Efforts to identify the magic 
bullet that would more selectively target lymphocytes to prevent allograft rejection have 
been a primary focus in transplantation research for many years. Early attempts were 
based on findings that the depletion of lymphocytes by drainage of the thoracic duct in 
rats had an immunosuppressive effect (71). This approach was also attempted clinically 
(11). However, the need for this expensive and inconvenient therapy for 30 days prior to 
transplant (72) prevented its wide application in the clinic (73).  
 The idea of using polyclonal antibodies specific for lymphocytes to prevent 
cellular immunity was proposed by Metchnikoff in 1899 (11). The utility of this crude 
mixture, called heterologous antilymphocyte globulin (ALG), for transplantation was 
shown in a rat skin graft model (74). For clinical studies, horses were immunized with 
human leukocytes, and the ALG was produced from the serum (11, 75). Although this 
approach was efficacious when used in conjunction with azathioprine and prednisone, 
(76), high levels of variability between batches made widespread clinical use at that time 
problematic.  
 The discovery of hybridoma technology by Kohler and Milstein (77) brought us 
one step closer to Ehrlich’s magic bullet. This technology spurred the development of the 
monoclonal antibody (mAb) as a therapeutic. The first clinically used mAb was called 
OKT3 or Muromonob-CD3 (M-CD3), and was raised against the CD3 determinant of T 
cells. Administration of OKT3 has had some clinical success (11), as has other T-cell 
specific mAbs, such as alemtuzumab (anti-CD52) (78), Daclizumab (79) and Basiliximab 
(80) (anti-CD25α). Efilizumab is a monoclonal antibody reactive against the CD11α 
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chain of leukocyte-function associated antigen 1 (LFA-1) mAb. In mice, anti-LFA-1 
treatment has been successful in promoting long term survival of heart allografts (81), 
although it is unclear if the mechanism involves blocking T-cell activation, proliferation 
or migration. 
Problems with immunosuppression 
 To date, although we are arguably much closer to Ehrlich’s magic bullet, we have 
yet to discover a clinical therapeutic that successfully modulates the alloimmune response 
without leaving the patient at risk for severe infections or the development of cancer 
(82,83). Indeed, the toxicity, and associated illnesses, resulting from these medications 
leads to a large percentage of adult patients being non-compliant with their medications 
(84). Despite the great advances clinical transplantation has enjoyed in the last 50 years, 
there are still many hurdles to overcome to make permanent acceptance of allogeneic 
grafts a reality. Considering the cumulative effects of these drugs and the young age of 
many that are in great need for life-saving transplantation, we undoubtedly need better 
reagents that will more consistently allow the permanent, immunosuppression-free 
survival of allografts.  
Transplantation of Allogeneic Stem Cells 
Background 
 Like allogeneic organ transplantation, the transplantation of allogeneic 
hematopoietic stem cells (HSC) is a potential curative therapy for a variety of human 
diseases, including hereditary diseases of the blood (reviewed in 85), metabolic disorders 
(reviewed in 86), autoimmune disease (reviewed in 87) and cancer (reviewed in 88,89). 
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These allogeneic stem cells can come from several sources, including umbilical cord 
blood or bone marrow. Alternatively, stem cells can be “mobilized” to accumulate in the 
peripheral blood of donors by administrating the granulocyte stimulating factor (G-CFS) 
analog, Neupogen (filgrastim). Regardless of the source of the cells, the limitations 
currently faced in allogeneic stem cell transplantation are substantial. The most 
concerning limitation currently is the inevitable development of graft versus host disease 
(GVHD). 
Graft Versus Host Disease 
 Early allogeneic bone marrow engraftment studies showed that irradiated mice 
infused with allogeneic bone marrow and splenocytes developed a “secondary disease”, 
the symptoms of which were diarrhea, weight loss, skin changes and liver abnormalities 
(90). In 1963, reports of the first clinically successful bone marrow transplantation 
describe an unfortunate correlation between the murine studies and clinical findings (91, 
11). The patient developed a chronic disease similar to secondary disease described in 
mice, and committed suicide 2 years after the transplant. Secondary disease, also called 
secondary syndrome, was later recognized to be the result of the infusion of functional 
donor lymphocytes into the host. In 1966, Rupert E. Billingham put forth a series of 
requirements for the development of this “reverse rejection” reaction, termed GVHD (92, 
90). First, the graft must contain immunocompetent cells. Second, the recipient must be 
incapable of rejecting the transplanted cells. Third, the recipient and donor must express 
different tissue antigens (90). This third component demonstrates the importance of 
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matching HLA antigens between the donor and recipient in bone marrow transplantation, 
even more so than in solid organ transplantation (93).  
  Following allogeneic bone marrow transplantation, the incidence of GVHD is 
directly related to the degree of MHC mismatch (reviewed in 94,95,96). Clinically, 
GVHD is also seen in patients who received a transplant of perfectly MHC-matched bone 
marrow (97). This rejection occurs due to differences in minor histocompatibility 
antigens between the donor and recipient (98). As many as 40% of patients receiving 
bone marrow transplants from HLA-identical donors develop acute GVHD in response to 
antigenic differences that lie outside of the HLA loci (97). Thus, even under optimal 
conditions, the risks associated with allogeneic stem cell transplantation remain high.  
Classifications of Graft versus Host Disease 
 Clinical GVHD can be classified based on the time of onset after transplant or by 
histological findings. In both cases, the classifications are described as acute or chronic. 
For epidemiological purposes, acute GVHD is defined as having an onset within 100 
days of transplant, and chronic GVHD begins any time thereafter (98). However, the 
histopathological changes usually associated with acute GVHD can occur after the 100 
day mark. Like the histological changes, clinical symptoms of these two disorders are 
also distinct from each other. For example, acute GVHD often affects skin, liver and the 
gastrointestinal tract whereas chronic GVHD can affect a wide range of tissues (98). The 
diversity in the clinical manifestations of GVHD greatly complicates the investigation 
into the mechanisms underlying this terrible disease.  
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Incidence of GVHD 
 The development of GVHD remains the most common complication of allogeneic 
stem cell transplantation (99). The development of acute GVHD is the most prevalent 
cause of morbidity in hematopoietic stem cell recipients, and accounts for up to 40% of 
the mortality in these patients. Additionally, three months after transplantation of 
allogeneic HSC up to 50% of surviving patients will be affected by chronic GVHD (100). 
Clearly, a better understanding of these mechanisms and a reliable therapeutic 
intervention to prevent GVHD while maintaining the immunological benefits of 
allogeneic stem cell transplantation are needed in order to maximize the potential of this 
life-saving procedure (98). 
The need for improved experimental models of human alloimmunity 
Detailed understanding of complex biologic and pathologic processes requires an in vivo 
system that can be manipulated experimentally. Because of obvious ethical constraints 
inherent to studies in humans, the creation of animal models that faithfully recapitulate 
the human immune system are crucial for both the basic scientific and medical research 
communities. Rodent models of human diseases have greatly expanded our knowledge of 
disease processes without placing patients at risk for adverse events (101,102). 
Unfortunately, not all findings in animal studies are successfully translated to clinical 
interventions for human disease (103-105). Immunological studies for transplantation and 
autoimmune diseases have proven particularly difficult due in part to differences between 
murine and human immune systems (106-108).  
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A small animal model possessing a functional human immune system would aid the 
research and medical communities in many ways. First, it would circumvent the 
frustrations associated with failures of translation from the bench to the clinic. Second, a 
much more detailed in vivo analysis of human immunity would be possible. Third, new 
therapeutics and protocols for the prevention of diseases mediated by allo- or autoreactive 
cells could be investigated, with the added ability to investigate mechanisms of action 
without putting patients at risk. Finally, with the advancement of monoclonal antibodies 
as therapeutics, it would allow for investigations of human specific reagents in a setting 
in which detailed mechanistic studies could be performed. 
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CHAPTER II: HUMANIZED MOUSE MODEL 
Background 
 The term “humanized” mouse is used to describe many experimental systems. 
Here, it refers to the engraftment of human hematopoietic cells into an immunodeficient 
mouse. There are variations of this model that differ in both the host mouse strain and in 
the source of human hematopoietic cells. Each of these models has its advantages and 
limitations, and the choice of model systems must be made based on the specific 
parameters the investigator wishes to study. For instance, the introduction of 
hematopoietic stem cells (HSC) obtained from umbilical cord blood allows studies of the 
developing human immune system in vivo. In contrast, mice engrafted with human 
PBMC are useful for studying human specific infectious reagents, and the allo- and 
autoimmune processes in vivo.  
Rationale 
  While much has been learned from the study of mouse models of immunology, 
differences between the murine and human immune system often complicate the direct 
extrapolation of these data to the clinic. For example, much of our knowledge of type 1 
diabetes emanates  from studies in the nonobese diabetic, or NOD mouse. Specific 
reagents developed in the NOD mouse have been put into clinical trials, and have 
uniformly been found unsuccessful. Because of inconsistencies between the murine and 
human immune system, a small animal model of the human immune system would be a 
useful tool to bridge the gap between the bench and the bedside without putting patients 
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at risk. For this purpose, we have developed a humanized mouse model of the human 
alloimmune response. 
History of humanized mouse models 
CB17-scid 
 The first milestone in the world of humanized mice was the discovery of the 
Prkdcscid mutation (protein kinase, DNA activated, catalytic polypeptide; severe 
combined immunodeficiency) mutation in CB17 mice (109). This mutation introduces a 
stop codon (110) into a gene encoding the catalytic subunit of a DNA-dependant protein 
kinase (111-115). The absence of functional Prkdc expression results in a failure to 
activate a DNA recombinase enzyme (116) which, in turn, results in a failure of V(D)J 
recombination of the lymphocyte antigen receptors (115,117,118) and a general absence 
of mature, functional B and T lymphocytes (119). As a result, these mice were able to 
support engraftment with human PBMC (120), fetal liver and thymus (121) and HSC 
(122). Although the early demonstrations of human cell engraftment were a successful 
“proof of principal,”, the levels of human cell engraftment in these models was extremely 
low (0.01-0.1%).  
 Several characteristics of  CB17-scid mice limited the utility of this model for the 
study of the function of engrafted human cells. First, despite being homozygous for the 
scid mutation, some adult mice bearing the scid mutation developed functional 
lymphocytes (123). This phenomenon, called “leakiness”, affected from 2-23% of young 
adult mice and as many as 90% of older mice. Second, the defective DNA repair 
machinery, in addition to disrupting lymphocyte development, also resulted in an 
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enhanced sensitivity to ionizing radiation (124), which markedly reduces the lifespan of 
irradiated mice. Third, perhaps in response to the absence of adaptive immunity, CB17-
scid mice have been shown to have enhanced function of the innate immune system 
compared to the wild-type strain (125). It was hypothesized that the enhanced innate 
immune function, and increased natural killer (NK) cell activity in particular (126) 
remained a barrier to the engraftment of human cells (127).  
 Efforts to overcome these limitations included the creation of mice lacking 
recombination activating gene 1 (Rag1) (128) or Rag2 (129) expression. This approach 
more specifically disrupted lymphocyte development, and did overcome the radiation 
sensitivity of scid mice. However, barriers to human cell engraftment presented by intact 
innate immune function remained (127).  
 In an effort to overcome the barrier presented by high levels of innate immunity in 
CB17-scid mice, the scid mutation was introduced onto several different murine 
backgrounds (131). Mice harboring the scid mutation on the NOD background 
consistently reached levels of human cell engraftment that were 5 to10-fold higher than 
other strains when injected with PBMC (131) or human spleen cells (132). In 1995, these 
studies firmly placed the NOD-scid model as the “gold standard” for human engraftment 
studies.  
NOD-scid 
 The NOD mouse is a well characterized model of spontaneous autoimmune 
diabetes (133). These mice have been reported to have multiple immune defects, 
including defects in macrophage development and function (134,135) an inability to 
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activate the hemolytic complement pathways (136), and decreased NK cell activity 
(133,137). Preventing the development of lymphocytes in the NOD mouse by introducing 
the scid mutation onto this background resulted in an animal that did not develop 
autoimmune diabetes and retained many of the innate immune defects of the parent strain 
(125).  
 The NOD-scid mouse is resistant to the leakiness seen in CB17-scid mice, as only 
about 10% of mice have immunoglobulin detectable in their serum at 6 months of age 
compared to 90% of CB17-scid mice at the same age (125). Similarly NOD-scid mice are 
able to retain allogeneic skin grafts over long periods of time, suggesting an absence of 
functional T-lymphocytes (125).   
Levels of engraftment of human PBMC in NOD-scid mice are higher than that 
seen in CB17-scid mice (131). Because of this, these mice were used to establish a model 
of human islet allorejection (138). In this model, mice were rendered diabetic with a dose 
of streptozotocin, a toxic chemical structurally similar to glucose. Streptozotocin is able 
to enter insulin-producing β-cells through a glucose transporter. Once inside the β-cell, it 
causes DNA damage which ultimately renders the animal diabetic. In the NOD-scid 
model of human allorejection, chemically diabetic NOD-scid mice were transplanted 
with a combination of isolated human islets of Langerhans and MHC-disparate human 
PBMC. Although higher levels of human cell engraftment were attained, only partial 
rejection of human islets was seen (138).  
Despite the improvements that the NOD-scid strain presents over previous 
models, many limitations remained to using these mice as hosts for human cell 
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engraftment. First, the radiosensitivity conferred by the scid mutation would not be 
improved by the NOD background. Second, NOD-scid mice have a mean lifespan of only 
8 months due to the development of fatal thymic lymphomas (125,139). Over 70% of 
NOD-scid mice develop thymic lymphomas by 40 weeks of age (125,139), possibly due 
to an endogenous ecotropic murine leukemia provirus locus, called Emv30, expressed 
only in the NOD mouse (139). Third, while the engraftment of human PBMC in NOD-
scid mice is much improved over the CB17-scid mouse, the level of human cell 
engraftment is still relatively low (1-10%) (131). This may be due to the remaining NK 
cell activity in NOD-scid mice (125). In an effort to increase further the engraftment of 
human cells, methods for genetically blocking the development of NK cells were tested.  
Genetic block in NK cell activity 
 The first of three stains of immunodeficient mice that were developed to 
genetically disrupt NK cell activity was the NOD-scid β2mnull mouse (140). As expected, 
these mice lack NK cell activity and engraft with human PBMC at higher levels than 
NOD-scid mice. However, problems remain with the use of this strain for long term 
studies of human cell engraftment. First, the lifespan of these mice proved to be even 
shorter than that seen in NOD-scid mice, primarily because the thymic lymphomas that 
develop in  NOD-scid mice occur even earlier in life in NOD-scid β2mnull mice (140). 
Second, because β2-microblobulin is also involved in regulating iron absorption 
(141,142), these mice develop severe hemachromatosis (140).  
 The second immunodeficient mouse strain genetically modified to lack NK cell 
activity was the NOD Rag1null Prf1null strain (143). As perforin (Prf1) is the key mediator 
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of NK cell killing (144,145), NK cells were able to develop but were not able to function 
properly (143). As expected, the lack of NK cell function did result in an increased 
engraftment of human PBMC and HSC. As these mice harbor the Rag1 mutation rather 
than the scid mutation, they are also relatively radioresistant (143). Although this model 
represents a step in the right direction, the engraftment levels in these mice remained 
variable between donors and among recipients of a single donor. 
NOD-scid IL2rγnull mouse 
 The third immunodeficient mouse strain created to genetically disrupt NK cell 
activity was the NOD-scid IL2rγnull mouse. Deficiency of IL2rγ in humans results in X-
linked SCID (146). The IL2rγ chain is required for high affinity binding and signaling 
through IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 receptors (147,148). NOD-scid IL2rγnull 
mice do not develop the thymic lymphomas observed in NOD-scid mice. The resulting 
increase in median lifespan ( >89 weeks) compared to that seen in NOD-scid mice (39 
weeks) makes longer term experiments possible (149). In addition to the absence of 
mature lymphocytes, dendritic cell maturation defects, and other innate immune 
deficiencies seen in NOD-scid mice (149), NOD-scid IL2rγnull mice also completely lack 
NK cell activity. This is due to the absence of this cell population, as NK cells require 
signaling through the IL-2 receptor for survival (149). Importantly, we have previously 
reported that NOD-scid IL2rγnull mice are able to support 6-fold higher levels of human 
PBMC engraftment compared to NOD-scid mice (149). It is the PBMC-engrafted NOD-
scid IL2rγnull mouse that will be the focus of this thesis. 
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Specific Goals and Thesis Aims 
 Detailed knowledge of the mechanisms utilized by the human immune system in 
vivo is prerequisite to developing specific immunomodulators for use in clinical 
transplantation. Studies in the human population that would address these questions are 
not possible for obvious ethical reasons. Small animal models of the human immune 
system are an important tool to bridge the gap between laboratory results and clinical 
science. Currently available small animal models of human immunity have only partially 
reflected clinical findings. We hypothesized that the human PBMC engrafted NOD-scid 
IL2rγnull mice, termed the hu-PBMC-NOD-scid IL2rγnull model, would be superior to 
previous models in its ability to accurately engraft with a functional human immune 
system in vivo. The goal of this thesis project was to investigate if a murine model of 
human immune function based on the NOD-scid IL2rγnull mouse engrafted with PBMC 
could more accurately represent alloimmunity as it exists clinically. To achieve this goal, 
we devised the following specific aims: 
Aim 1: Test the hypothesis that a functional human immune system can be 
engrafted in NOD-scid IL2rγnull mice. Chapter IV presents data investigating this 
hypothesis. Four goals were addressed: 1) Optimize the parameters for human PBMC 
engraftment.  
2) Investigate kinetics of human PBMC engraftment 3) Evaluate the function of engrafted 
human PBMC by allogeneic challenge. 4) Begin the in vivo studies of human therapeutics 
in PBMC-engrafted NOD-scid IL2rγnull mice. 
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Aim 2: Test the hypothesis that the enhanced engraftment of PBMC in NOD-scid 
IL2rγnull mice will allow a xenograft model of GVHD that accurately mimics clinical 
disease. Chapter V presents data investigating this hypothesis. Three goals were 
addressed: 1) Define the parameters of GVHD development in the human PBMC 
engrafted NOD-scid IL2rγnull mice. 2) Investigate the role of host MHC class I and class 
II in the development of GVHD in human PBMC engrafted NOD-scid IL2rγnull mice. 3) 
Evaluate the modulation of GVHD in human PBMC engrafted NOD-scid IL2rγnull mice 
using clinically relevant human therapeutics. 
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CHAPTER III: MATERIAL AND METHODS 
Animals 
NOD/LtSz-Prkdcscid (NOD-scid) and NOD.cg-PrkdcscidIl2rgtm1Wjl/SzJ (abbreviated as 
NOD-scid IL2rγnull) NOD-scid IL2rγnull β2mnull, NOD-scid IL2rγnull Abo, NOD-scid 
β2mnull, NOD-scid Abo and NOD-scid β2mnull Abo mice were obtained from colonies 
developed and maintained by LDS at The Jackson Laboratory (Bar Harbor, ME). All 
animals were certified to be free of Sendai virus, pneumonia virus of mice, murine 
hepatitis virus, minute virus of mice, ectromelia, lactate dehydrogenase-elevating virus, 
mouse poliovirus, Reo-3 virus, mouse adenovirus, LCMV, polyoma, Mycoplasma 
pulmonis, and Encephalitozoon cuniculi. They were housed in a specific pathogen-free 
facility in microisolator cages, given autoclaved food and an alternating schedule of 
acidified water and a solution of sulfamethoxazole-trimethoprim (Goldline Laboratories, 
Ft. Lauderdale, FL) (140). Animals were maintained in accordance with the guidelines of 
the Institutional Animal Care and Use Committee of the University of Massachusetts 
Medical School and the recommendations in the Guide for the Care and Use of 
Laboratory Animals (Institute of Laboratory Animal Resources, National Research 
Council, National Academy of Sciences). 
GVHD Protocol 
NOD-scid IL2rγnull mice were irradiated with 2 Gy unless otherwise indicated and 
injected intravenously 4 hrs later with various doses of PBMC. In all experiments, mice 
were weighed 2 to 3 times weekly and the appearance of GVHD-like symptoms 
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including rapid weight loss (>15%), hunched posture, ruffled fur, reduced mobility, and 
tachypnea were used to determine time of euthanasia and is indicated as time of survival. 
Antibodies and Flow Cytometry 
FITC conjugated anti-human CD8 (clone HIT8a), PE conjugated anti-human CD4 (clone 
RPA-T4), PerCP conjugated anti-mouse Ly5 (clone 30-F11), APC-conjugated anti-
human CD45 (clone H130), Alexa 700 conjugated anti-human CD3 (clone UCHT1), and 
anti-mouse CD16/32 (clone 2.4G2) mAb were obtained from BD Pharmingen (San Jose, 
CA). Alexa 405 conjugated anti-human CD20 (clone 2H7) was obtained from AbD-
Serotec (Oxford, UK). 
At times indicated in the text, single-cell suspensions of spleens or bone marrow flushed 
from the femurs and tibias were prepared in RPMI 1640 and washed in complete PBS 
(Dulbecco’s PBS containing 0.1% sodium azide [Sigma-Aldrich, St. Louis, MO] and 1% 
fetal bovine serum [HyClone, Logan, Utah]). Blood was collected from the retro-orbital 
venous plexus of anesthetized mice using EDTA-coated capillary tubes (Drummond 
Scientific, Broomall, PA) and EDTA-treated 1.5 ml tubes (Eppendorf, Westbury, NY).  
Blood, single cell suspensions of splenocytes, or bone marrow were incubated in anti-
CD16/32 for 5 min at 4°C to block nonspecific Fc binding. Antibodies at the appropriate 
dilutions, previously determined by titration against human or mouse lymphocytes, were 
incubated with 106 spleen cells or 100µl of blood for 30 minutes at 4°C. Spleen cells and 
blood were then incubated with anti-mouse CD45 and fluorescence-conjugated anti-
human CD45 mAb plus anti-human CD3, anti-human CD4, anti-human CD8, and/or anti-
human CD20 mAb. Labeled spleen cells were washed, fixed with 1% paraformaldehyde 
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(Polysciences, Warrington, PA) in complete PBS. Blood samples were processed with 
FACS lysing solution (BD Biosciences, San Jose, CA) according to the manufacturer’s 
protocol. At least 20,000 events were acquired with an LSRII instrument (BD 
Biosciences, San José, CA) and analyzed using FlowJo Software (Mac version 8.2; Tree 
Star, Ashland, OR).  
For all analyses, anti-mouse CD45 staining was performed to exclude murine host cells 
from analysis, and only human CD45+ cells that were mouse CD45-negative were 
included in the analyses 150. Matching isotype antibodies were used as negative controls 
and the reported values have been corrected using these isotype control values (143). 
Levels of human CD45+ cells reaching 0.1% in the blood and 1.0% in the spleen at four 
weeks were considered as successfully engrafted mice (131,132,140,143).  
Collection of human PBMC 
Human PBMCs were obtained from healthy volunteers and blood donors, under signed 
informed consent in accordance with the Declaration of Helsinki and approval from the 
Institutional Review Board of the University of Massachusetts Medical School. PBMCs 
were collected in heparin and purified by ficoll hypaque density centrifugation. PBMCs 
were then suspended in RPMI for injection into mice at the doses and routes indicated. 
Quantification of Human Immunoglobulin 
Total human IgG and IgM in serum were quantified by ELISA as previously described 
(140). Briefly, 96 well plates were coated with goat-anti-human IgG F(ab’)2 or donkey-
anti-human IgM F(ab’)2 (Jackson ImmunoResearch, West Grove, PA). A mixture of 
biotinylated mouse-anti-human Ig lambda (clone JDC-12) and mouse-anti-human 
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IgKappa (clone G20-193; BD Pharmingen) was added, and streptavidin-alkaline 
phosphatase (Southern Biotech, Birmingham, AL) with 4-nitrophenyl phosphate (Sigma-
Aldrich) was used for detection. Total human IgG and IgM (Jackson ImmunoResearch) 
standard curves were run with each assay and Ig levels were determined from the curves. 
Optical densities of ELISA samples were read at 405 nm on a Maxline Emax plate reader 
(Molecular Devices, Sunnyvale, CA) according to the manufacturers recommendations.  
Human Cytokine Production 
NOD-scid IL2rγnullmice received 2 Gy total body irradiation using a Gammacell 40 
(Atomic Energy of Canada, Ottawa, Canada) four hours prior to receiving intravenous 
injections via the tail vein of 20x106 human PBMC. Plasma samples were collected from 
the retro-orbital venous plexus of anesthetized mice 1 hour, 4 hours and 24 hours after 
PBMC injection using EDTA-coated capillary tubes (Drummond Scientific, Broomall, 
PA) and EDTA-treated 1.5 ml tubes (Eppendorf, Westbury, NY). Plasma samples were 
stored at -80 until use. The Cytometric Bead Array Human Inflammation kit (BD 
Biosciences, San Jose, CA) was used following manufacturers recommendations to 
determine the concentration of human cytokines in the plasma samples.  
Mixed Lymphocyte Culture 
Murine stimulator cells were prepared by preparing single cell suspensions of spleens 
recovered from NOD-scid, NOD-scid-β2mnull, NOD-scid Abo, or NOD-scid β2mnull Abo 
mice. RBC were lysed with hypotonic ammonium chloride lysing solution, and the 
nucleated cells were washed in RPMI supplemented with 10% FBS, 100 U/ml penicillin 
G, 100 µg/ml streptomycin, and 0.29 mg/ml L-glutamine (complete medium); counted; 
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and suspended in complete medium at 10x106 cells/ml. The stimulator cells were then 
exposed to 20 Gy 137Cs radiation using a Gammacell 40 (Atomic Energy of Canada).  
Murine stimulator cells (5x106 in 500µl) were added to each well of 24-well tissue 
culture plate (Falcon, Becton Dickinson Labware, Lincoln Park, NJ). Responder human 
PBMC were labeled with 1µm CFSE (Molecular Probes, Eugene, OR, 151)). Labeled 
responder cells (1x106 in 500µl of medium) was added to triplicate wells containing 
murine stimulator cells, and the plates were incubated for 7 days at 37°C in a humidified 
atmosphere of 95% air and 5% CO2. Cells were then harvested, stained for cell surface 
markers and analyzed with an LSRII instrument (BD Biosciences). Mod-Fit software 
(Verity, Topsham, ME) was used to determine precursor frequency.  
Human Islet Transplantation 
The procurement and use of all human tissues were performed under protocols approved 
by the Institutional Review Board of the University of Massachusetts Medical School. 
Human islets designated for research were obtained from the Juvenile Diabetes Research 
Foundation Islet Isolation Center at the University of Pittsburgh (Pittsburgh, PA) or the 
National Islet Cell Resource Center Program (NCRR). All islets were maintained in 
CMRL 1066 culture medium (Media Tech. Inc., Herndon, VA) containing 2.5% human 
albumin at 25°C in an atmosphere of 95% air 5% CO2 until transplanted. Islet viability, 
assessed by trypan blue dye exclusion, was 65–75% and islet cell purity, as determined 
using dithizone staining, was 60–75%. The islet yield was converted mathematically to a 
total number of islets with an average diameter of 150 µm [islet equivalents (IEQs)]. 
Human IEQs (3000–4000) suspended in RPMI were transplanted into spleen of NOD-
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scid IL2rγnull mice previously rendered chemically diabetic (blood glucose >450 mg/dl) 
by a single intraperitoneal (i.p.) injection of streptozotocin (150 mg/kg). The number of 
islets used for transplantation was determined from preliminary studies showing that 
3000–4000 human IEQs routinely reverse hyperglycemia in diabetic NOD-scid mice 
(138). Non-fasting plasma glucose levels were determined using an Accu-Chek Active 
glucometer (Hoffmann-La Roche, Basel, Switzerland) at twice-weekly intervals 
following transplantation to monitor islet xenograft function.  
Quantification of human insulin and C-reactive peptide 
A commercially available assay specific for human insulin and c-peptide and not cross-
reactive with mouse insulin or C-peptide was used (Linco Research, St Charles, MO). 
This assay utilizes differentially labeled fluorescent beads coated with relevant antibody 
to either insulin or C-peptide and then phycoerythrin labeled secondary antibodies to 
quantify the hormones using a standard curve. The assay was read using a Luminex 
analyzer (Luminex, Austin, TX). Manufacturers instructions were followed and the inter- 
and intra- assay coefficents of variation were 7.2 and 2.6 % for insulin and 4.2 and 7.3% 
for C-peptide, respectively. 
Histopathological analyses 
Tissues were recovered from mice at necropsy, fixed in 10% buffered formalin, and 
embedded in paraffin. Sections 5 µm thick were cut. For routine histology, sections were 
stained with hematoxylin and eosin. The sections were evaluated by Dr. Bruce Woda or 
Dr. Oded Foreman without knowledge of the experimental design. For 
immunohistochemistry, sections were heated at 60°C for 30 min, then deparaffinized and 
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hydrated through a series of xylene and alcohol baths before staining. The slides were 
microwaved in a proprietary citrate-buffered Ag retrieval solution (BioTek Solutions, 
Santa Barbara, CA) for 5 min in an 800-W microwave oven. After replenishment of this 
solution the slides were microwaved for another 5 min, then cooled for 20 min. 
Immunohistochemical staining was performed with mAbs specific for human CD45, 
insulin and glucagon using a DakoCytomation EnVision Dual Link system implemented 
on a Dako Autostainer Universal Staining System (Dako; Denmark). The sections were 
counterstained with hematoxylin. 
Statistics 
All measures of variance are presented as standard error of the mean (SEM). Significance 
of difference of independent means was assumed for p values of <0.05. Comparisons of 
two means used the independent samples t-test and comparisons of three or more means 
used one-way analyses of variance using GraphPad Prism software (Graphpad Software, 
San Diego, CA).  
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CHAPTER IV: A NEW HU-PBL MODEL FOR THE STUDY OF HUMAN ISLET 
ALLOREACTIVITY BASED ON NOD-SCID MICE BEARING A TARGETED 
MUTATION IN THE IL-2 RECEPTOR GAMMA CHAIN GENE 
INTRODUCTION 
Immunodeficient NOD-scid mice bearing a targeted mutation in the IL2 receptor 
common gamma chain (IL2rγnull) readily engraft with human hematopoietic stem cells. 
Data presented in this chapter describe the analysis of human peripheral blood 
mononuclear cells (PBMC) as to their ability to engraft in NOD-scid IL2rγnull mice. We 
also describe the kinetics of human cell engraftment, define the optimal cell dose, and 
investigate the influence of injection route on engraftment levels. Even at low PBMC 
input, NOD-scid IL2rγnull mice reproducibly support high human PBMC engraftment that 
plateaus within 3-4 weeks. In contrast to previous stocks of immunodeficient mice, we 
observed low intra- and inter-donor variability of engraftment. NOD-scid IL2rγnull mice 
rendered hyperglycemic by streptozotocin treatment return to normoglycemia following 
transplantation with human islets. Interestingly, these human islet grafts are rejected 
following injection of HLA-mismatched human PBMC as evidenced by return to 
hyperglycemia and loss of human C-peptide. These data suggest that humanized NOD-
scid IL2rγnull mice may represent an important surrogate for investigating in vivo 
mechanisms of human islet allograft rejection. 
 
 
 
  
36 
RESULTS 
1. Engraftment of Human PBMC in NOD-scid and NOD-scid IL2rγnull Mice 
NOD-scid mice have represented the “gold standard” for engraftment studies involving 
human lymphohematopoietic cells for over 10 years (127). Several reports have shown 
that NOD-scid IL2rγnull mice support higher levels of engraftment with human 
hematopoietic stem cells (HSC) than do NOD-scid mice (152), but their ability to support 
engraftment with human PBMC has not been reported. To determine this potential, we 
compared the engraftment of human PBMC in NOD-scid IL2rγnull and NOD-scid mice. 
Cohorts of each strain were injected i.p. or i.v. with 20x106 human PBMC and analyzed 
four weeks later for engraftment of human lymphohematopoietic cells. The i.p. route of 
injection is the method routinely used for engraftment studies of human PBMC in NOD-
scid mice whereas few reports have suggested successful human PBMC engraftment in 
NOD-scid mice following i.v. injection (127,132,153,154).  
Four weeks after i.p. injection of 20x106 PBMC, levels of human CD45+ cell engraftment 
in the blood of NOD-scid Il2rγnull mice (20.7±2.6%, N=26) were significantly higher than 
those achieved in NOD-scid mice (0.1±0.1%, N=11, p<0.0001, Figure 1, panel A). 
Engraftment of human CD45+ cells in the spleen of NOD-scid IL2rγnull mice (52.8±4.2%, 
N=26) was also significantly higher than that achieved using NOD-scid mice (1.2±0.8 %, 
N=11, p<0.0001, Figure 1, panel B). Based on these data, all subsequent experiments 
were performed in NOD-scid lL2rγnull mice. 
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Figure 1. Engraftment of human PBMC into NOD-scid IL2rγnull and NOD-scid mice. 
NOD-scid IL2rγnull and NOD-scid mice were injected with 20x106 human PBMC i.v. or 
i.p. Engraftment of the peripheral blood (Panel A) or spleen (Panel B) was evaluated by 
flow cytometry 4 weeks later. Bars represent median engraftment levels. (A) NOD-scid 
IL2rγnull mice achieved higher levels of engraftment in the peripheral blood following i.p. 
(p<0.0001) or i.v. (p<0.0001) injection. (B) Engraftment of human CD45+ cells in the 
spleen was higher in NOD-scid lL2rγnull mice than in NOD-scid (p<0.0001). Each circle 
represents an individual mouse. 
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2. Optimal route of injection for engraftment of human PBMC  
We next compared three routes of in vivo PBMC delivery that are commonly used; 
intravenous (i.v.), intraperitoneally (i.p.), and intrasplenic (i.s.) (127,132,138,153,154). 
Engraftment of human CD45+ cells in the peripheral blood four weeks following i.v. 
injection of 20x106 human PBMC (37.6±2.7%) was significantly higher than in mice 
injected either i.p. (20.3±2.8%) or i.s. (22.4±6.4%; p<0.05, Figure 2, panel A). As 
expected, engraftment of human CD45+ cells in the spleen of NOD-scid IL2rγnull mice 
was significantly higher than that achieved in NOD-scid mice four weeks after i.v. 
injection (66.1±4.1% vs. 0.1±0.1%, respectively, p<0.0001, Figures 1 and 2). The 
percentages (Figure 2, panel B) and numbers (Figure 2, panel C) of human CD45+ cells 
engrafted in the spleen four weeks following i.p., i.v., and i.s. injection were statistically 
similar. 
3. Kinetics of Human PBMC Engraftment 
To evaluate the kinetics of human cell engraftment, NOD-scid IL2rγnull mice were 
injected i.v. with 20x106 human PBMC. Engraftment of human CD45+ cells in the 
peripheral blood and spleen was then evaluated weekly over the next four weeks. The 
percent of human cells increased through three weeks in both blood (Figure 3, panel A) 
and spleen (Figure 3, panel B). Higher levels of engraftment were observed in the spleen 
(69.5±6.3%) as compared to that achieved in the blood (37.6±2.7%) at 4 weeks. The 
number of human CD45+ cells in the spleen also reached a plateau by three weeks 
following PBMC injection (4.5±1.7x107, Figure 3, panel C). The majority of the 
engrafted human cells in the blood and spleen were CD3+ (>98%). The CD4:CD8 ratio of 
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CD3+ T cells in the blood was variable at week one, but approximated a ratio of ~1:1 at 
two weeks and remained at this ratio through the four week observation period in both 
the blood and spleen (Table 1). We next determined the circulating levels of human IgM 
and IgG. Four weeks after injection of 20x106 human PBMC, high levels of IgM (39.3 ± 
18.8 µg/ml, N=5) and IgG (40.9 ± 11.1 µg/ml, N=5) were observed in the serum of 
engrafted mice, suggesting the engraftment of activated human B cells or xenoactivation 
of transferred naïve B cells.  
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Figure 2. Routes of human PBMC injection. 
NOD-scid IL2rγnull mice were injected via the i.p., i.s., or i.v. route with 20x106 PBMC. 
Engraftment of human CD45+ cells was evaluated 4 weeks later by flow cytometry. Bars 
represent median levels of human cell engraftment. Panel A: Intravenous injection of 
PBMC resulted in significantly higher average percentages of CD45+ in the blood of 
recipients as compared to either i.p. (p<0.05) or i.s. injection (p<0.05). Panel B: The 
percentages of human CD45+ cells engrafted in the spleen were statistically similar for 
mice injected with PBMC via the i.p., i.s., or i.v. route. Panel C: The average numbers of 
CD45+ cells recovered from the spleens following i.p., i.s., i.v. injection were statistically 
similar between all groups. Each circle represents an individual mouse. 
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Figure 3. Kinetics of PBMC engraftment.  
NOD-scid IL2rγnull mice were injected i.v. with 20x106 PBMC and evaluated by flow 
cytometry weekly over a 4 week period. Panel A: The percentage of human CD45+ cell 
engraftment in the peripheral blood increased significantly each week through 4 weeks 
(p<0.01). Panel B: Engraftment of the percentage of human CD45+ cells in the spleen 
increased significantly each week through 3 weeks (p<0.01), reaching a plateau that did 
not increase further at week four (p=n.s.). Panel C: The numbers of human cells 
recovered from the spleens of engrafted mice increased from through week two (p<0.05). 
No further increase in the number of human CD45+ cells in the spleen was achieved at 
week three or week four (p=n.s.). Each circle represents an individual mouse. 
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4. Cell dose dependence of human CD45+ cell engraftment 
Robust human CD45+ cell engraftment in NOD-scid mice following PBMC injection 
requires i.p. injection of as many as 50x106 to 300x106 human PBMC (127,152,155). For 
many studies, particularly for experiments using PBMC obtained from children, this 
represents a significant limitation as fewer cells are typically available. As most 
published studies have used the i.p. route of PBMC injection, we first determined the 
engraftment levels of human CD45+ cells in NOD-scid IL2rγnull mice following i.p. 
injection of 20x106 and 50x106 human PBMC. As shown in Figure 4, panels A and B, the 
percentage of human CD45+ cells engrafted at four weeks was not elevated in recipients 
of 50x106 as compared to recipients of 20x106 PBMC (p=N.S.).  
 Having demonstrated that i.v. injection of 20x106 human PBMC led to high levels 
of human CD45+ cell engraftment (Figures 1-3), we next determined if lower cell doses 
would lead to human CD45+ cell engraftment in NOD-scid lL2rγnull mice. Human CD45+ 
cells were detected in the blood and spleen of mice four weeks after injection of as few as 
1-5x106 PBMC (Figure 4, panels C and D). Increasing the number of injected PBMC to 
10x106 increased the level of engraftment, again with higher levels of engraftment 
observed in the spleen as compared to the blood (Figure 4, panels C and D). Intravenous 
injection of 10x106 or more PBMC resulted in engraftment of human CD45+ cells in 
100% of the recipients. 
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Table 1. Engrafted T-lymphocytes develop an activated phenotype  
Cell Subset Day 7 Day 14 Day 21 Day 28 
Peripheral Blood     
Total CD4+ (%) 69.3±8.3  45.7±10.0 40.3±13.3 56.1±19.9 
% CD45RO+/CD4+ 53.9±12.3 89.0±4.9  84.8±5.5 93.9±3.9 
% HLA-DR+/CD4+ 5.2±2.7 13.0±6.4  50.6±10.3 56.2±23.8 
Total CD8+ (%) 30.0±10.3 52.8±10.4 54.1±13.6 42.5±20.6 
% CD45RO+/CD8+ 63.3±21.9 88.1±6.0 86.3±6.5 93.8±4.5 
% HLA-DR+/CD8+ 11.9±7.6 22.6±14.5 49.3±6.0 51.2±18.8 
CD4:CD8 Ratio 2.3:1 0.9:1 0.7:1 1.3:1 
Spleen     
Total CD4+ (%) 20.5±2.9 44.6±6.5 55.5±2.0 51.5±22.3 
% CD45RO+/CD4+ 77.7±4.7 84.1±0.9 83.8±4.4 95.2±3.6 
% HLA-DR+/CD4+ 11.4±2.3 4.3±2.0  49.7±10.9 35.7±24.6 
Total CD8+ (%) 70.8±6.9 48.8±8.2 43.4±1.6 44.2±20.7 
% CD45RO+/CD8+ 19.8±14.3 44.4±13.3 94.0±4.1 95.6±2.8 
% HLA-DR+/CD8+ 62.7±10.1 48.5±10.2 52.7±9.9 48.0±27.9 
CD4:CD8 Ratio 0.3:1 0.9:1 1.3:1 1.2:1 
Table 1. NOD-scid IL2rγnull mice were injected i.v. with 20x106 human PBMC and the 
percentage and phenotype of engrafted human CD3+ cells that were CD4+ or CD8+ in the 
blood and spleen were analyzed by flow cytometry at the times indicated (n=3). 
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Figure 4 
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Figure 4. Cell dose dependence of human CD45+ cell engraftment 
NOD-scid IL2rγnull mice were injected by the indicated route and human PBMC cell dose. 
The engraftment of human CD45+ cells was determined 4 weeks later. Panels A and B: 
Mice were injected i.p. with 20x106 or 50x106 human PBMC. The percentages of human 
cell engraftment in the peripheral blood (Panel A) and spleen (panel B) are shown. 
Injection of 20x106 or 50x106 PBMC resulted in statistically similar levels of human cells 
in the blood (p=n.s.) or the spleens (p=n.s.). Panels C and D: Mice were injected i.v. with 
the indicated number of human PBMC. The percentage of human CD45+ cells in the 
blood (Panel C) increased from undetectable levels (<0.01%) following injection of 
1x106 PBMC to readily detectable levels following injection of 5x106 PBMC. Injection of 
10x106 (p<0.025) or 20x106 (p<0.025) human PBMC led to increased engraftment. No 
statistically significant differences were observed in the percentage of human CD45+ 
cells following injection of 10x106 and 20x106 human PBMC. Panel D: The percentage 
of human CD45+ cells in the spleen following injection of 1x106 human PBMC increased 
with increasing cell doses to 10x106 human PBMC (p<0.025) but was not increased 
further by injection of 20x106 human PBMC (p=n.s.). Each circle represents an 
individual mouse 
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5. Intra- and inter-donor variability of human CD45+ cell engraftment 
Intra- and inter-donor variability in human CD45+ cell engraftment in recipients of 
human PBMC has been a major limitation in previous PBMC-engrafted immunodeficient 
mouse models (152). To assess the variability of human CD45+ cell engraftment in NOD-
scid IL2rγnull mice, we determined engraftment levels among recipients of single PBMC 
donors or cohorts of mice given PBMC from different donors. The percentages of human 
CD45+ cells in the blood and spleen, as well as the number of human CD45+ cells in the 
spleen and blood, were quantified 4 weeks following i.v. injection of human PBMC into 
NOD-scid IL2rγnull mice.  
In contrast to the low frequency of engraftment and the low levels of human PBMC 
observed in engrafted NOD-scid mice (127,131,152), all NOD-scid IL2rγnull mice injected 
with 20x106 PBMC from the same donor engrafted with human CD45+ cells (Figure 5, 
panels A and B). While cells from all donors led to engraftment in NOD-scid IL2rγnull 
mice, the percentage of human CD45+ cells varied considerably, particularly in the 
peripheral blood. In the spleen, however, the differences between individual mice 
engrafted with cells from the same donor were small. 
  
47 
 
Figure 5. Intra- and inter-donor variability in engraftment among PBMC donors 
NOD-scid IL2rγnull mice were injected intravenously with 20x106 PBMC from seven 
different donors (x-axis, A-G). Human CD45+ cells in the peripheral blood (Panel A) and 
spleen (Panel B) were analyzed 4 weeks later. There was no statistical difference in 
engraftment levels achieved among different PBMC donors in either the blood or spleen. 
Each circle represents an individual mouse. 
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6. Engrafted human T-lymphocytes rapidly acquire an activated phenotype  
It has previously been reported that the majority of human lymphocytes engrafted into 
immunodeficient mice acquire an activated/memory phenotype (CD45RO, MHC  
class II-positive) (150). To investigate the kinetic progression of human CD3+ T cell 
activation in NOD-scid IL2rγnull engrafted mice, splenocytes were isolated from mice at 
various times after i.v. injection of PBMC and stained for the expression of activation 
markers. We observed a rapid upregulation of MHC class II on CD3+ T cells and a shift 
over time to expression of CD45RO, peaking at approximately three weeks (Table 1).  
7. Human islet allograft rejection in NOD-scid IL2rγnull mice engrafted with allogeneic 
human PBMC 
We have previously shown that i.p. injection of 300x106 human PBMC into chemically 
diabetic NOD-scid mice transplanted with human allogeneic islets leads to islet graft 
damage, and in some cases complete rejection (138). To investigate human islet allograft 
rejection in NOD-scid IL2rγnull mice, we first determined whether human islet grafts 
would restore normoglycemia in chemically diabetic mice transplanted i.s. with human 
islets. In 14 of 14 diabetic recipients receiving 3000-4000 human islet equivalents, 
normoglycemia (blood glucose <250 mg/dl) was achieved within five days (Figure 6). 
Simultaneous i.v. injection of 20x106 allogeneic human PBMC in 100% (8/8) islet graft 
recipients led to rapid rejection of the islets and a return to hyperglycemia within 21 days. 
To determine if human PBMC could reject established human islets grafts, 
normoglycemic mice provided islet transplants 37 days earlier were injected i.v. with 
20x106 human PBMC. Two of three mice reverted to hyperglycemia within three weeks 
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following PBMC injection (Figure 6). Blood glucose levels were increasing in the third 
mouse prior to termination of the experiment.  
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Figure 6. Human islet allograft transplantation in chemically diabetic Hu-PBL-
NOD-scid IL2rγnull mice. 
Chemically diabetic NOD-scid IL2rγnull mice were transplanted intrasplenically with 
3000-4000 human islet equivalents. Cohorts of these mice also received intravenous 
injections of HLA-mismatched human PBMC from one of 3 donors on the same day. 
Blood glucose levels were monitored twice weekly to evaluate the function of the 
transplanted islets. At day 37, 3 mice bearing functioning human islet grafts that had not 
received human PBMC were injected intravenously with 20x106 HLA-mismatched 
PBMC. Vertical bars indicate censored data. 
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8. Human islet histology 
Analysis of human islets transplanted into the spleens of diabetic mice that were not 
given human PBMC showed intact islets with no islet inflammation 32 days after 
transplantation (Figure 7, panel A). In contrast, islets in mice injected with human  
PBMC displayed a marked cellular infiltration around and within the islet grafts (Figure 
7, panel B). Staining with anti-human CD45 mAb demonstrated no evidence of human 
CD45+ cells in mice given islet grafts only (panel C), whereas an intensive human CD45+ 
cellular infiltrate was observed in the islet grafts of PBMC-injected mice (panel D). Islet 
grafts in mice not engrafted with human PBMC exhibited intact islets with a normal 
endocrine cell mass for insulin (panel E) and glucagon (panel G). The spleens of mice 
given human PBMC showed multiple nodules of lymphoid cells. Some islets in mice 
given human PBMC were devoid of endocrine cells and some showed a few residual 
endocrine cells (illustrated in Figure 7, panels F and H). 
 To confirm human islet function in transplanted mice, human insulin and C-
peptide levels were determined in serum obtained 9-12 days (all mice were 
normoglycemic at this time) and 19-22 days following islet transplantation. In mice given 
islet transplants only, circulating levels of human insulin and C-peptide were readily 
detected at both time points (Figure 8). In mice transplanted with human islets and 
provided allogeneic human PBMC on the day of islet transplantation, high levels of 
human insulin and C-peptide were detected at days 9-12. In contrast, by days 19-22, time 
points at which hyperglycemia had returned in human PBMC injected mice, only low 
levels of human insulin or C-peptide were detected in the serum (Figure 8), consistent 
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with the high blood glucose levels and morphological evidence suggesting that the human 
islets had been rejected by the engrafted human PBMC.  
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Figure 7 
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Figure 7. Human islet allograft histology 
Human islets were transplanted into the spleen of chemically diabetic NOD-scid IL2rγnull 
mice. These mice either received no further treatment (left column) or were injected 
intravenously on the same day with 20x106 allogeneic PBMC (right column). Sections 
were stained with H&E (A and B), anti-human CD45 (C and D), anti-insulin (E and F) or 
anti-glucagon (G and H).  
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Figure 8. Serum insulin and C-peptide in human islet transplanted NOD-scid 
IL2rγnull mice 
Serum samples were collected from mice that received human islet transplants alone 
(solid bars; n=6) or in conjunction with 20x106 allogeneic PBMC (striped bars; n=8). 
Levels of human insulin (A) and C-peptide (B) were determined at early (day 9-12) or 
late (19-22) time points. Panel A: Levels of human insulin were similar at 9-12 days (9±5 
vs. 5±3 mU/L, p=ns), but became statistically different by 19-22 days (23±20 vs. 1±2 
mU/L, p=0.0073). Panel B: Serum C-peptide levels were similar at 9-12 days (600±376 
vs. 493±253 pmol/L, p=ns), but became statistically different by 19-22 days (1172±572 
vs. 73±136 pmol/L , p=0.0002). 
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9. Raptiva modulates PBMC engraftment in NOD-scid IL2rγnull mice. 
 Having established that human PBMC can home to and destroy allogeneic human 
islets transplanted within the spleen of NOD-scid IL2rγnull mice, investigations into 
mechanisms used by therapeutic agents to modulate allograft rejection are now possible.  
The initial question we addressed was the effect the therapeutic agent has on the ability of 
PBMC to engraft in NOD-scid IL2rγnull mice. For these preliminary studies, we chose to 
investigate the mechanism(s) of action of Raptiva. 
 Raptiva, or Efalizumab, is a humanized IgG1 anti-human LFA-1 mAb. The 
antibody interrupts the binding of LFA-1 to its receptor, intercellular adhesion molecule-
1 (ICAM-1). LFA-1 is the only integrin expressed on all leukocyte lineages (156), and as 
such it plays many roles in the setting of an immune response. Functions associated with 
LFA-1 include mediating the intercellular interactions needed for T lymphocyte-mediated 
cytotoxicity, lymphocyte responses, and trafficking of leukocytes into inflamed tissues 
(157-159 ). Its binding partner, ICAM-1, is expressed on vascular endothelial and 
epithelial cells (160,161). The potential for targeting LFA-1/ICAM-1 interactions as an 
immunotherapy for enhancing other agents for prolonging islet allograft survival has 
recently been reviewed (162). 
 Raptiva is currently approved for the clinical treatment of psoriasis and in kidney 
transplantation. Clinical trials are now underway to test if Raptiva can enhance islet 
allograft survival, prevent rheumatoid arthritis, or prevent graft-versus-host disease.  
 In murine models, anti-mouse LFA-1 has been shown to modulate T cell 
activation, migration, and islet allograft rejection. More recently, LFA-1 has been found 
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to function as a costimulatory molecule (162). Administration of blocking antibodies to 
mouse LFA-1 has been used to enhance solid organ and cell transplants, including islets 
(163-166). Unfortunately, Raptiva does not bind mouse LFA-1, and cross-reacts poorly 
with non-human primates. However, human LFA-1 and mouse ICAM-1 interact 
effectively, obviating issues of species-specificity (167). These two facts make the Hu-
PBL-NOD-scid IL2rγnull model an ideal system with which to investigate the mechanisms 
by which anti-human LFA-1 mAb mediates its actions in vivo.  
 We have begun to investigate the effect of Raptiva on human PBMC engraftment 
and migration. NOD-scid IL2rγnull mice were injected intravenously with 20x106 human 
PBMC. Group 1 received only PBMC (labeled PBL day 14 and PBL day 28 on Figure 
9A and PBL on Figure 9B). Group 2 was given Raptiva (200mg) at the time of PBMC 
injection (day 0) and on days 1 and 7 after PBMC injection (labeled anti-LFA-1 day 0 on 
graph). Group 3 was given Raptiva on days 14 and 21 after PBMC injection (labeled anti-
LFA-1 day 14 on graph).  
 The percentage of human CD45+ cells in the blood of Group 1 at day 14 was 
9.4±6.3% and increased to 50.9±14.3% on day 28 (Figure 9A). In contrast, mice given 
Raptiva beginning on the day of PBMC injection (Group 2) had few (0.3±0.3%) human 
CD45+ cells in their blood on day 28 (p<0.0001 vs. Group 1). Mice permitted to engraft 
for 2 weeks prior to injection of Raptiva on days 14 and 21 (Group 3) had an intermediate 
level of human CD45+ cells in their blood (24.2±12.6%, p<0.01 vs. Group 1 and p<0.005 
vs. Group 2, Figure 9A). The percentage of human CD45+ cells in the spleen on day 28 in 
Group 1 was 62.8±10.7% (Figure 9B). Mice given Raptiva beginning on the day of 
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PBMC injection (Group 2) had few (2.6±2.9%) human CD45+ cells in the spleen on day 
28 (p<0.0001 vs. group 1). In contrast, mice permitted to engraft for 2 weeks prior to 
injection of Raptiva on days 14 and 21 (Group 3) had an high level of human CD45+ cells 
in their spleen on day 28 (57.5±14.7%) that was equivalent to that observed in mice not 
given Raptiva (p=NS vs. Group 1 and p=0.0002 vs. Group 2, Figure 9B). 
 These data provide insights into the mechanisms by which Raptiva functions in 
vivo. First, Raptiva prevents the activation and/or expansion of naïve human T cells in 
vivo as Group 2 had low levels of human PBMC at day 28 as compared to untreated 
controls (Group 1). Second, Raptiva is not a depleting antibody as initiation of treatment 
on day 14 (Group 3) after allowing human PBMC to engraft and expand in the mice does 
not deplete the already engrafted human cells. Third, Raptiva prevents the migration of 
human T cells from the spleen into the blood. The blood levels of human CD45+ cells in 
Group 3 were reduced whereas the levels of human CD45+ cells in the spleen of Group 3 
were similar to that of untreated controls (Group 1). Finally, Raptiva does not prevent the 
continued expansion of activated human T cells as the levels of splenic human CD45+ 
cells were similar in Groups 1 and 3.  
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Figure 9 
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Figure 9. Modulation of human PBMC engraftment and migration in Hu-PBL-
SCID mice injected with anti-LFA-1. 
 NOD-scid IL2rγnull mice were injected intravenously with 20x106 human PBMC 
prepared from two different donors. Panel A: PBL day 14 and PBL day 28 received only 
PBMC (Group 1 in text) and were analyzed on day 14 and 28, respectively. Anti-LFA-1 
day 0 (Group 2 in text) was given Raptiva (200µg) at the time of PBMC injection (day 0) 
and on days 1 and 7 after PBMC injection and analyzed on day 28. Anti-LFA-1 day 14 
(Group 3 in text) was given Raptiva on days 14 and 21 after PBMC injection and 
analyzed on day 28. Panel B: PBL (Group 1), anti-LFA-1 day 0 (Group 2) and anti-LFA-
1 day 14 (Group 3) are the same mice as in Panel A and were analyzed on day 28. 
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SUMMARY 
In this chapter, we demonstrate the improved engraftment of human PBMC in NOD-scid 
IL2rγnull mice compared to the previous “gold standard” NOD-scid strain. We then 
defined the optimal route of injection, optimal cell dose and the kinetics of human cell 
engraftment into NOD-scid IL2rγnull mice. The functionality of engrafted human T-cells 
was demonstrated by the ability of engrafted human PBMC to target allogeneic human 
islets transplanted into the spleen of chemically diabetic NOD-scid IL2rγnull mice. 
Finally, in preparation for in vivo studies investigating the mechanisms by which Raptiva 
prevents allograft rejection, we describe the effects of Raptiva on the engraftment of 
human PBMC. We determined that Raptiva prevents activation or proliferation of naïve 
T-cells but not activated T-cells. Further, Raptiva does not deplete T-cells in vivo, but 
does impact the ability of T-cells to migrate from the spleen.  
Together, the data presented in Chapter 4 describe a new model system for mechanistic 
studies of human allograft rejection, and how potential therapeutics may affect these 
mechanisms in vivo. 
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CHAPTER V: XENOGRAFT-VERSUS-HOST DISEASE IN THE HU-PBL-NOD-
SCID IL2RγNULL MODEL 
INTRODUCTION 
Graft versus host disease remains the major limitation to the success of allogeneic 
bone marrow transplantation (99). The development of a small animal model of the 
human immune system for the study of GVHD has followed a similar path as the 
development of models of human allorejection described in the introduction.  
For example, human PBMC engraftment in mice harboring the Prkdcscid (protein 
kinase, DNA activated, catalytic polypeptide; severe combined immunodeficiency) 
mutation (120) only occurred at very low levels, and then only after i.p. injection of a 
high number of human PBMC (50x106 to 100x106 cells). Most of the human cells that did 
engraft became anergic (168,169). Only a small percentage of these unconditioned CB17-
scid mice engrafted with human PBMC developed a GVHD-like disease (170), making 
the Hu-PBL-scid mouse a poor model for this particular line of research.  
 The NOD-scid strain of mice have many defects in the innate immune function 
that together allow for higher human PBMC engraftment compared to CB17-scid mice 
(171). However, the level of engrafted human cells remained quite low (172). As the 
level of T cell chimerism has been directly correlated with the development of GVHD 
(170), it is not surprising that only a fraction of NOD-scid mice injected with PBMC 
develop symptoms consistent with clinical GVHD.  
As the primary barrier to achieving higher levels of human cell engraftment in 
immunodeficient mice remains NK cells, several groups have reported efforts to decrease 
the activity of this cell population by targeted cell depletion (173,174) or genetic 
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modification (175,176). Recently, two approaches have been reported to genetically 
impair the development of NK cells in mice. First, an H2d mouse deficient in both Rag2 
and the common gamma chain of the IL-2 receptor (IL2rγ) had some advantages 
compared to NOD-scid mice. A higher level of human cell engraftment was reached, and 
engraftment was successful with 90% of human PBMC donors tested. However, 
extensive preconditioning of the recipient with total body irradiation and macrophage 
depletion using clodronate-containing liposomes was required and still did not eliminate 
the variability in human cell engraftment and the development of GVHD symptoms in 
these mice (175).  
A second approach to genetically inhibit the maturation of NK cells was based on 
a NOD-scid β2mnull mouse (176). This strain of mouse was able to support human cell 
engraftment and the development of GVHD without the requirement for macrophage 
depletion. However, retro-orbital injection of 10x106 purified human T-lymphocytes into 
lightly irradiated mice produced GVHD in only 59% of the animals whereas PBMC 
injection via the tail vein exhibited only transient engraftment and failed to induce 
GVHD (176). 
 Immunodeficient NOD-scid lL2rγnull readily engraft with human PBMC. In 
Chapter 5, we report a new human into mouse xenograft model of GVHD based on 
intravenous injection of PBMCs via the tail vein into lightly conditioned NOD-scid 
IL2rγnull mice. These mice consistently (100%) develop GVHD following injection of as 
few as 5x106 PBMC, regardless of the PBMC donor used. As in human disease, the 
development of GVHD was highly dependent on host expression of MHC class I and 
  
64 
class II molecules. Interrupting the TNFα signaling cascade with etanercept, a therapeutic 
in clinical trial for human GVHD, delayed the onset and progression of disease.  
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RESULTS 
1. Low dose irradiation accelerates GVHD in NOD-scid IL2rγnull mice injected with 
human PBMC 
NOD-scid IL2rγnull mice engrafted with human PBMC develop a gradual weight loss and 
exhibit hunched posture, anemia, decreased mobility and ruffled fur (177), symptoms that 
are consistent with GVHD. A recently reported human into mouse xenograft model of 
GVHD describes the use of total body irradiation and host macrophage depletion as 
requisite preconditioning for consistent induction of GVHD (175). As we have observed 
untreated NOD-scid IL2rγnull mice more readily engraft with high levels of human PBMC 
than do BALB/c-Rag1null IL2rγnull mice and eventually develop GVHD symptoms (177), 
we asked whether low dose irradiation alone would accelerate the onset and progression 
of GVHD.  
 NOD-scid IL2rγnull mice given 2 Gy of total body irradiation and injected 
intravenously via the tail vein with 20x106 human PBMC developed an accelerated form 
of GVHD leading to decreased survival as compared to mice that received PBMC in the 
absence of irradiation preconditioning. (Figure 10A. MST=11 vs. MST=34 days; 
p<0.0001). As expected, 2 Gy sublethal irradiation had no effect on the survival of 
otherwise untreated mice (Figure 10A). To determine if weight loss was a sensitive 
predictor of GVHD, irradiated and non-irradiated NOD-scid IL2rγnull mice were injected 
with 20x106 human PBMC and weighed three times weekly for approximately 6 weeks. 
We found that weight loss was a strong predictor of survival in mice engrafted with 
human PBMC (Figure 10B).  
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Figure 10. Sublethal irradiation accelerates GVHD in Hu-PBMC-NOD-scid 
IL2rγnull Mice.  
NOD-scid IL2rγnull mice received either 2 Gy irradiation only (solid line, n=7), 20x106 
human PBMC i.v. (dashed line, MST=34 days, n=8, 3 PBMC donors), or both 2 Gy 
irradiation and PBMC (dotted line, MST=11, n=13, 3 PBMC donors). (A) Survival of 
irradiated, PBMC injected, mice was significantly shorter that mice receiving PBMC 
alone (p<0.0001). (B) Changes in total body weight relative to weight at the beginning of 
the experiment are shown.  
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2. Kinetics of GVHD development is dependent on inoculum cell dose 
We next determined the effect of varying PBMC cell dose on the development of GVHD. 
Published models of xeno-GVHD in irradiated immunodeficient mice have injected 
between 15x106 and 30x106 human PBMC and have inconsistent induction of GVHD 
symptoms (175,178). However, we have observed that as few as 5x106 PBMC 
consistently results in engraftment in non-irradiated NOD-scid IL2rγnull mice (177). To 
determine the effect of cell dose on disease development, we injected 5x106, 10x106 or 
20x106 human PBMC intravenously into 2 Gy irradiated mice. There was a strong 
correlation between the median survival time (MST) and cell dose (Figure 11; MST=22 
days, 17 days, and 12 days, respectively). However, all mice given even the low dose of 
5x106 from multiple donors developed GVHD. 
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Figure 11. GVHD progression is dependent on PBMC cell dose.  
Survival of NOD-scid IL2rγnull mice that received 200 cGy TBI prior to injection of 
20x106 (solid line, MST=12 days, n=18, 4 PBMC donors), 10x106 (dashed line, MST=17 
days, n=11, 4 PBMC donors) or 5x106 (dotted line, MST=22 days, N=8, 3 PBMC 
donors), human PBMC i.v.  
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3. Murine MHC stimulates human PBMC proliferation in vitro 
It has been hypothesized that human cell CD4+ T cell expansion in immunodeficient mice 
is driven by xenoreactivity to mouse MHC class II (168). However, in previous models 
using CB17-scid or NOD-scid mice, CD8+ T cells were found to predominate in the 
engrafted recipient (131,132,143). Furthermore, in NOD-scid IL2rγnull mice, both CD4+ 
and CD8+ T cells engraft at high levels (177) suggesting that reactivity to both mouse 
MHC class I and class II may occur. 
 To begin to determine the role of host MHC on human PBMC engraftment, we 
first determined the percentage of human T cells that proliferate in vitro in response to 
murine MHC class I and class II molecules. CFSE-labeled human PBMC were cultured 
alone or in the presence of splenocytes as antigen-presenting cells that were obtained 
from NOD-scid, NOD-scid β2mnull (MHC class I deficient), NOD-scid ABnull (MHC class 
II deficient), or NOD-scid β2mnull ABnull (MHC class I and class II deficient) mice. 
As expected (168) a lower proportion of human CD4+ cells proliferated in response to 
NOD-scid ABnull and NOD-scid β2mnull ABnull (both MHC class II deficient) splenocytes as 
compared to NOD-scid splenocytes (p<0.025 and 0.05, respectively, Figure 12, left 
panel). Alternatively, a lower proportion of human CD8+ cells proliferated in response to 
NOD-scid β2mnull and NOD-scid β2mnull ABnull (both MHC class I deficient) splenocytes 
as compared to NOD-scid splenocytes (both p<0.025, Figure 12, right panel). These data 
suggest that some, but not all proliferation of human T cells in immunodeficient NOD-
scid mice is in response to reactivity to host MHC class I and class II molecules.  
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Figure 12. In vitro proliferation of human PBMC in response to murine class I or 
class II MHC. CSFE-labeled human PBMC were cultured alone or in the presence of 
APC splenocytes obtained from NOD-scid, NOD-scid β2mnull, NOD-scid Aβnull or NOD-
scid β2mnull Aβnull mice for 7 days. The precursor frequency index of one experiment 
representative of 3 independent experiments is shown (± 1 s.d.).  
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4. Recognition of host MHC class I drives the development of GVHD 
We found that a higher proportion of human PBMC proliferate in response to in vitro 
stimulation with cells expressing murine MHC class I as compared to stimulator cells 
expressing murine MHC class II (Figure 12). Based on this observation and the previous 
report that host MHC class II drove human T cell proliferation (168), we hypothesized 
that mice lacking MHC Class I or class II expression would exhibit delayed development 
of GVHD. To test this, NOD-scid IL2rγnullβ2mnull (deficient in MHC class I) or NOD-
scid-IL2rγnullAβnull mice (deficient in MHC class II) were irradiated with 2 Gy and 
injected with 5x106 human PBMC. Surprisingly, we observed that NOD-scid-IL2rγnull 
Aβnull mice were highly susceptible to GVHD, although disease progression was slightly 
but significantly delayed as compared to that observed in NOD-scid IL2rγnull mice 
expressing both MHC molecules (Figure 13, MST=22 vs. 21 days, respectively, p=0.02). 
More interestingly, NOD-scid IL2rγnullβ2mnull mice were relatively resistant to disease 
development (MST=44 days), which was significantly delayed relative to that observed 
in NOD-scid IL2rγnull Aβnull (p=0.001) and NOD-scid IL2rγnull (p<0.0001) mice.  
 To determine if decreased human CD45+ cell engraftment was the mechanism by 
which GVHD was significantly delayed in NOD-scid IL2rγnullβ2mnull mice, peripheral 
blood was analyzed at the time of euthanasia of animals exhibiting GVHD. Decreased 
human CD45+ cell engraftment was observed in both NOD-scid IL2rγnullβ2mnull mice 
(13.9±6.9%, p=0.007) and NOD-scid IL2rγnull Aβnull mice (18.1±8.3%, p=0.006) 
compared to mice expressing both MHC molecules (53.6±4.4%, Figure 14A). 
Surprisingly, human CD45+ cell engraftment in mice deficient in MHC class I was not 
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significantly different from that seen in mice deficient in MHC class II (p=N.S.). As 
expected, we observed that NOD-scid IL2rγnullβ2mnull null mice have significantly higher 
CD4/CD8 ratios in the blood (p=0.01), spleen (p=0.01) and bone marrow (p=0.0009) 
than the other two strains (Figure 14B).  
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Figure 13. Mice deficient in MHC Class I expression are resistant to GVHD.  
Survival of NOD-scid IL2rγnull (dashed line, MST=21 days, n= 21, 6 PBMC donors), 
Nod-scid IL2rγnullAβnull (solid line, MST=22 days, n=23, 6 PBMC donors) and NOD-scid 
IL2rγnullB2mnull (dotted line, MST=46.5 days, n=10, 4 PBMC donors) following TBI and 
i.v. injection of 5x106 cells. 
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Figure 14. Decreased PBMC engraftment in MHC deficient mice 
Engraftment of Nod-scid IL2rγnull , Nod-scid IL2rγnullAβnull and Nod-scid IL2rγnullB2mnull 
mice that received 2 Gy and i.v. injection of 5x106 cells was determined. Peripheral 
blood, spleen and bone marrow of moribund mice were analyzed. (A) Engraftment of 
human CD45+ cells in the peripheral blood of moribund mice. (B) Ratio of the percent of 
human CD4+ vs. human CD8+ cells recovered from the peripheral blood, spleen and bone 
marrow of moribund mice. 
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5. Soluble TNFα receptor delays progression of GVHD 
TNFα has been reported to have an important role in the pathogenesis of GVHD (90,179-
181). In Phase I and II clinical trials, anti-TNFα antibody treatment decreased the 
severity of disease (182). Similarly, blocking TNFα with etanercept, (Enbrel, a soluble 
TNFα receptor) as part of a GVHD treatment regimen was shown to be efficacious (183).  
To determine if etanercept would delay or prevent GVHD, we first treated NOD-scid 
IL2rγnull mice with two doses of etanercept injected i.p. prior to irradiation and 
intravenous injection of 20x106 human PBMC. Pretreatment with etanercept significantly 
increased the survival of mice from a MST of 12 to 16 days, with one mouse surviving to 
day 41 (Figure 15A, p=0.007). To determine if a more aggressive drug regimen would 
prolong survival further, mice were injected with etanercept every 3 days following 
PBMC injection in addition to the pretreatment dosing. This dosing regimen increased 
survival (MST = 23 days) significantly over the two dose regimen (Figure 15A, p=0.01). 
For all groups, weight loss consistently correlated with disease progression (Figure 15B).  
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Figure 15 
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Figure 15. Soluble TNFα receptor delays progression of GVHD.  
(A) Survival of NOD-scid IL2rγnull mice that received 20x106 PBMC i.v. four hours after 
2 Gy TBI (solid line, MST=12 days, n=18, 7 PBMC donors), with etanercept 
pretreatment of 100 µg/injection on days -3 and -1 prior to injection of PBMC (dashed 
line, MST= 16 days, n=18, 7 PBMC donors) or etanercept pretreatment plus 100 µg 
every three days (MST=23 days, n= 12, 4 PBMC donors). (B). The average weight 
change in irradiated mice that received PBMC alone (red line), PBMC plus etanercept 
pretreatment (blue line) or etanercept pretreatment plus 100 µg every three days (green 
line) is shown as the percent of starting weight. The numbers shown correspond with the 
surviving mice at each time point.  
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6. Etanercept-dependent disease prevention at lower PBMC doses 
The injection of 20x106 human PBMC led to a robust GVHD with no mouse surviving 
past day 25 (Figure 15A). We next determined the effect of both etanercept dosing 
schedules on GVHD development in mice injected with 5x106 human PBMC. All mice 
given etanercept exhibited delays in the development of GVHD (Figure 16). Both the 
two dose etanercept pretreatment and repeat dose etanercept treatment significantly 
increased survival compared to mice receiving only 5x106 PBMC (p=0.03 and p=0.0003 
respectively). However, we observed no statistical difference in survival between the two 
treatment groups (Figure 16A, p=0.15). Interestingly, 3 of 25 mice that were pretreated 
with etanercept as well as 6 of 24 mice that received repeat doses of etanercept remained 
GVHD-free at the end of the observation period.  
One possible mechanism by which etanercept could delay disease development would be 
to reduce human PBMC engraftment. To investigate this, the percentage of human cells 
engrafted in the mice was determined 14 days after irradiation with 2 Gy and injection of 
5x106 human PBMC alone or in combination with the two etanercept dosing regimens. 
The percentage of human CD45+ cells was significantly decreased in the peripheral blood 
(p<0.0001), spleen (p<0.0001) and bone marrow (p<0.0001) in mice given either 
etanercept dosing regiment as compared to non-drug treated mice (Figure 16B).  
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Figure 16. Etanercept-dependent disease prevention at lower PBMC doses. 
(A) Survival of NOD-scid IL2rγnull mice that received 5x106 PBMC i.v. four hours after 
200 cGy TBI (solid line, MST=22 days, n=15, 7 PBMC donors), with etanercept 
pretreatment of 100 µg/injection on days -3 and -1 prior to injection of PBMC (dashed 
line, MST=28 days, n=25, 7 PBMC donors) or etanercept pretreatment plus additional 
100 µg etanercept injections every three days (dotted line, MST=47 days, n=24, 7 PBMC 
donors). PBMC vs etanercept pretreatment, p=0.03; PBMC vs multidose etanercept, 
p=0.0003; etanercept pretreatment vs multidose etanercept, p=ns. (B) Mice received 2 Gy 
four hours prior to 5x106 PBMC. 14 days later, human CD45+ cell engraftment in the 
blood (left panel), spleen (middle panel) and bone marrow (right panel) was evaluated by 
flow cytometry. Etanercept treatment deceased human CD45+ engraftment in all tissues 
tested (p<0.0001).  
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7. Infiltration of human CD45+ cells in peripheral tissues  
 Previous reports have described infiltration of human cells into various tissues of 
immunodeficient mice developing GVHD-like symptoms (175). To evaluate human cell 
infiltration in irradiated NOD-scid IL2rγnull mice injected with human PBMC, spleen, gut, 
lung, liver, skin and tongue of mice developing clinical symptoms of GVHD were 
studied histologically. Human CD45+ cells were detected in the spleen, gut, lung and 
liver (data not shown). There were 3 mice that received 5x106 PBMC along with the 
multidose etanercept treatment regimen that began to lose fur 50-60 days after PBMC 
injection. Interestingly, in one mouse that was losing fur, we observed infiltration of 
human cells into the skin immediately in the area of hair loss (Figure 17). The infiltrate 
of human lymphocytes is present at the dermal epidermal junction (Figure 17B), and 
consists of both CD4+ (Figure 17D) and CD8+ (Figure 17E) lymphocytes in a lichenoid 
pattern with cells arranged in a banded configuration parallel to the epidermis. 
8. Expression of human cytokines in mice with GVHD 
There has been conflicting reports regarding the production of human cytokines in 
humanized mice. For example, in their H2d Rag2nullγcnull based model, van Rijn et al 
(175) reported detectable levels of human IFNγ, GM-CSF, IL-6, IL-10, IL-13, high levels 
of IL-1α, IL-2, IL-15 and IL-18. The presence of IL-4, IL-8 and TNFα were not detected. 
In contrast, human IFNγ and IL-1β, but not IL-2, IL-4, IL-6, IL-10 and TNFα, were 
detected in the NOD-scid β2mnull model of GVHD reported by Nervi et al, (176). To 
determine the levels of human cytokines in the plasma of etanercept-treated or untreated 
NOD-scid IL2rγnull mice we recovered plasma at various times after PBMC injection and 
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determined the level of human cytokines using a flow cytometry-based methodology 
(184).  
 With the exception of one animal in the PBMC alone group, we did not detect 
human IL-1β, IL-6, IL-10 or IL12-p70 above background levels in either etanercept 
treated or untreated mice at any time point tested (data not shown). IL-8 was detected at 
low levels in all mice at 1 hour and 4 hour timepoints, but was not detectable at the 24 
hours after PBMC injection.  
 Plasma levels of human TNFα in mice that received PBMC alone were not 
statistically different from background levels from mice that did not receive PBMC 
(Figure 18). Similarly, human TNFα levels in mice treated with etanercept were not 
statistically different from PBMC alone mice at 1 hour (12.7+/-12.4 vs 7.2+/- 6.4 pg/ml; 
n=6, p=0.39) or 2 hours post-PBMC injection (22.4+/- 14.8 vs 9.5+/-14.6 pg/ml; p=0.2). 
Surprisingly, 24 hours after PBMC injection, plasma levels of human TNFα were 
significantly higher in etanercept treated mice compared to mice that received PBMC 
alone (33.94+/-15.10 pg/ml vs 9.433+/-16.01 pg/ml; p=0.03).  
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Figure 17. Infiltration of human lymphocytes in the skin of NOD-scid IL2rγnull mice. 
Truncal skin from NOD-scid IL2rγnull mice 63 days after irradiation with 2 Gy and 
injection with 5x106 human PBMC. Infiltrate of lymphocytes is present at the dermal 
epidermal junction. Arrows point to human cell infiltration. (A) H&E 
(B) human CD45 (C) human CD3 (D) human CD4 (E) human CD8. (400X) 
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Figure 18. Plasma levels of human TNFα in etanercept-treated mice. 
Levels of human TNFα in plasma samples collected from untreated or etanercept-
pretreated mice 1 hour, 4 hours and 24 hours after PBMC injection. All mice received 2 
Gy 4 hours prior to i.v. injection of 5x106 PBMC from one of two PBMC donors. Each 
dot represents one mouse.  
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SUMMARY 
 
 In this chapter, we present evidence that low-dose total body irradiation of NOD-
scid Il2rγnull mice prior to intravenous injection with human PBMC results in a model of 
GVHD that develops more consistently than previously reported models. We also 
addressed the important role host MHC plays in the in the development of GVHD in this 
model. We then demonstrate that the disease that develops in NOD-scid Il2rγnull mice 
mimics the clinical disease in its response to soluble TNFα receptor, etanercept, and 
begin to investigate the mechanism underlying this activity.  
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CHAPTER VI: DISCUSSION 
An in vivo model of human allorejection 
 In Chapter IV, we report the development and characterization of the latest-
generation Hu-PBL-SCID mouse model, which takes advantage of the NOD-scid lL2rγnull 
strain and highlights its utility in a human islet allograft rejection system. We document 
the superior human PBMC engraftment in these mice and the corollary improvement in 
the robustness of the rejection of allogeneic human islet grafts compared to previous 
immunodeficient hosts (138). 
Superior engraftment with human PBMC 
 Immunodeficient mice with targeted mutations at the IL-2 receptor common γ 
chain locus (IL2rγnull) mice are gaining popularity as an immunodeficient host and have 
been shown to support high levels of human hematopoietic stem cell engraftment (152). 
Therefore, we sought to evaluate the NOD-scid IL2rγnull mouse for its ability to support 
human PBMC engraftment. We first demonstrate that the NOD-scid IL2rγnull mouse 
strain is a superior model for the engraftment of human PBMC as compared to the NOD-
scid strain (127). This is due in part to the complete absence of T and B lymphocytes in 
the NOD-scid IL2rγnull (149), i.e. no scid “leakiness” (132,172). More importantly, the 
IL2rγnull mutation completely blocks the development of host NK cells, a cell population 
that has been previously shown to be a barrier to human hematopoietic cell engraftment 
(125,126,140).  
 Importantly, NOD-scid IL2rγnull mice achieve high levels of human 
lymphohematopoietic cell engraftment following i.v. PBMC injection, a route of 
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administration that has not been routinely successful in NOD-scid mice (127,153,154). In 
fact, i.v. injection of PBMC in NOD-scid IL2rγnull mice resulted in significantly higher 
levels of human cell engraftment than either the i.p. or i.s. route of injection of PBMC. In 
addition to the improved levels of human PBMC engraftment, there are multiple reasons 
that i.v. injection of human cells into host mice is preferable to other injection routes. 
First, i.v. injection opens up the possibility of broader experimental manipulations for 
delivery of PBMC that does not require the surgery used for intrasplenic injection into the 
circulation. Second, i.v. injection puts human PBMC directly into the circulation whereas 
following i.p. injection, 7-14 days are required for human PBMC to drain from the 
peritoneal cavity into the circulation (131,140). Third, i.v. injection permits immediate 
interaction between the human immune system with the allograft, a situation that more 
accurately mimics the environment observed in clinical human transplantation protocols. 
Thus, the ability to engraft high levels of human PBMC at low cell doses following i.v. 
injection will permit experimental manipulations not previously possible in earlier 
generations of Hu-PBL-SCID mouse models (127).  
 Investigating the kinetics of human cell engraftment revealed that the human 
CD45+ cells present in the peripheral blood of the host mice increased throughout the four 
week observation period. However, both the percentages and numbers of human CD45+ 
cells in the spleen reached a plateau three weeks after PBMC injection, suggesting that 
homeostatic regulatory mechanisms may remain intact, even in this xenograft model 
system. In agreement with the notion of homeostatic regulation, increasing the initial i.v. 
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PBMC inoculum over 20x106 cells did not result in increased levels of human CD45+ 
cells present at four weeks (data not shown). 
 The ratio of human CD4+ to CD8+ cells recovered from the spleens of engrafted 
mice stabilized at an approximate ratio of 1:1 by the second week. Evaluation of the 
numbers of CD4+ and CD8+ human cells indicate that this change in CD4/CD8 ratio was 
primarily due to a relative increase in the absolute number of both the CD4+ and CD8+ 
cells over time (data not shown). The relative ratio of CD4:CD8 T cells more closely 
mimics that observed in the circulation of the PBMC donors rather than the skewed ratio 
towards CD8+ T cells previously observed in CB17-scid or NOD-scid PBMC 
engraftment models (131,132,143).  
 Two limitations of previously reported models for human PBMC engraftment in 
immunodeficient IL2rγnull mice have been the requirements for injection of large numbers 
of human cells and/or the necessity for irradiation or other preconditioning regimen of the 
host mice to achieve engraftment (175,178). In studies using H2d Rag2null IL2rγnull mice, 
human PBMC engraftment required 3.5 Gy irradiation and treatment with chlodronate-
containing liposomes to kill host monocytes and macrophages (and presumably human 
monocytes within the injected human PBMC population). Additionally, many of these 
mice rapidly developed a xenogeneic graft-versus-host disease and no functional analyses 
of the engrafted human immune system were performed in these studies. In contrast, all 
NOD-scid IL2rγnull mice injected with 20x106 human PBMC engrafted at high levels, 
with no graft-versus-host disease symptoms observed within the first 30 days, creating a 
window of opportunity for the study of the human immune response.  
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Furthermore, the successful engraftment of human hematolymphoid cells following 
injection of as few as 5x106 PBMC without the need for host preconditioning represents a 
substantial improvement over earlier models where 50x106 or more cells were injected, 
yet variability in engraftment remained. Indeed, injection of as few as 10x106 PBMC into 
NOD-scid IL2rγnull mice results in engraftment of 100% of the animals, emphasizing the 
dramatically lower PBMC dose needed for experimental protocols.  
 Large variations in engraftment levels obtained when using different PBMC 
donors, and in multiple mice injected with PBMC from the same donor has remained an 
obstacle to a reliable and reproducible small animal model of human immunity (185-
188), even in H2d Rag2null IL2rγnull mice (175). The NOD-scid IL2rγnull mouse has now 
overcome this limitation, with remarkably low variability in engraftment. We also 
achieve comparable levels of engraftment in multiple experiments using the same donor. 
Furthermore, previous reports indicate that PBMC obtained from a subset of donors fail 
to result in engraftment at all in immunodeficient mice (185). We have not observed this 
phenomenon in this model, as PBMC from all donors utilized to date have resulted in 
engraftment. The implication of improved engraftment at lower cell doses and with 
minimized recipient to recipient and donor to donor variability is that this model will be a 
much more stable platform for experimental manipulation. For example, at cell doses of 
10-20x106 PBMC per recipient, a sizable cohort of mice can be engrafted from the same 
donor using a routine venipuncture blood draw, thus eliminating the confounding 
variables associated with cohorts of recipients engrafted from multiple blood donors 
(which were required at the higher PBMC doses used to achieve engraftment in previous 
  
93 
models). In addition, we observed a significant expansion of the injected human PBMC, 
suggesting proliferation of the injected cells.  
Modeling islet allograft rejection 
Having concluded that NOD-scid IL2rγnull mice are superior hosts for human PBMC 
engraftment, we sought to test the functional aspects of the human immune system using 
a model of islet allograft rejection in humanized mice. In previous models of allorejection 
of human tissues in immunodeficient mice, both human islet grafts (138) and human skin 
grafts (189-191) are inconsistently or incompletely rejected by HLA-mismatched human 
PBMC. As a consequence, rejection often was determined post-facto by histopathological 
evidence, making this model difficult for use in interventional studies. This failure of 
complete rejection has been attributed in part to poor engraftment of human monocytes 
(192), presumably resulting in inefficient activation of the engrafted T cells. Inefficient T 
cell activation could render these cells anergic (150,168,169) and thus unable to mediate 
graft rejection. Consistent with this, we do observe a shift in the phenotype of engrafted T 
cells from expression towards CD45RO over time in mice that receive PBMC. The 
engrafted human PBMC, however, are not anergic and are able to completely reject 
HLA-mismatched human islet grafts in the spleens of recipient mice. Alternatively, the 
more physiological CD4:CD8 T cell ratio observed in PBMC-engrafted NOD-scid 
IL2rγnull mice may also be responsible for the more robust rejection by retaining the CD4+ 
T cells needed to provide “help” to efficiently activate alloreactive cytotoxic CD8 T cells 
that destroy the islet graft.  
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Interestingly, we also observed that our model would permit the engraftment of the 
human islets that have healed-in and restored normoglycemia prior to injection of human 
PBMC to mediate allograft rejection. This is an important advance, because the quality of 
human islets for research can be inconsistent and thus a confounding variable when 
PBMC and islets are co-engrafted as in previous models. This variation of the model now 
permits the function of the human islets to first be confirmed in vivo prior to the injection 
of human PBMC to study islet rejection.  
A model of human GVHD 
 In Chapter V, we describe a robust model of GVHD based on the NOD-scid 
IL2rγnull stock of mice. These mice consistently develop GVHD following low dose 
irradiation and intravenous injection of low numbers of PBMC. Using this model, we 
documented the relative contribution of host MHC class I and class II to human cell 
engraftment and disease expression using unique newly generated stocks of MHC-
deficient NOD-scid IL2rγnull mice. This new model of GVHD was then used to 
demonstrate that etanercept mediates its protective effect in part by decreasing the 
engraftment of human PBMC and blocking the TNFα signaling pathway. 
 We have previously shown NOD-scid IL2rγnull mice to be superior hosts in their 
ability to support human PBMC engraftment relative to NOD-scid mice or BALB/c-
Rag1null IL2rγnull mice (177,193). In unconditioned NOD-scid IL2rγnull mice injected 
intravenously with 20x106 human PBMC, we observed the gradual development of 
symptoms consistent with GVHD over the course of 4 to 6 weeks. To investigate whether 
we could optimize this model for the study of GVHD, we first determined the effects of 
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preconditioning with low dose irradiation. It has been reported the development of 
GVHD in other model systems is enhanced by administration of 3-3.5 Gy whole body 
irradiation (175,178,194). However, even in mice given irradiation pre-conditioning, 
engraftment and GVHD development was inconsistent and relatively high numbers of 
PBMC were required (175,178) or GVHD was observed following only very specific 
injection routes and cell doses (194). For example, a GVHD model based on the NOD-
scid β2mnull mouse exhibited disease only after retro-orbital but not intravenous tail vein 
injection of human PBMC (194). Furthermore, a minimum inoculum of 10x106 purified 
T cells was required for mice given 2.5 Gy of irradiation, and then only 59% of the mice 
developed the disease. In contrast to the previously reported models of GVHD, we 
observed that 100% of NOD-scid IL2rγnull mice treated with low dose irradiation (2 Gy) 
and injected with 20x106 human PBMC consistently developed disease between 10 and 
20 days. Furthermore, we observed that 100% of irradiated mice developed GVHD 
following intravenous injection with as few as 5x106 PBMC and that this effect was not 
donor dependent. 
Contribution of host MHC to GVHD development 
 Using this optimized model, we next investigated the mechanism driving the 
engraftment of human PBMC and the development of GVHD in irradiated NOD-scid 
IL2rγnull mice. It has previously been suggested that the development of GVHD is 
dependent on the relative engraftment of human T lymphocytes which is likely driven by 
recognition of host MHC (170). In murine allo-GVHD models, mice deficient in MHC 
class I or class II develop delayed CD8+ or CD4+ mediated GVHD, respectively (195), 
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suggesting that alloreactivity to both host MHC alleles is important in disease 
pathogenesis. In human-mouse xenoreactive models, early experiments evaluating human 
T cells isolated from CB17-scid mice demonstrated that human CD4+ T cells recovered 
from engrafted mice had TCRs specific for murine MHC class II (168). However, the 
predominance of CD8+ cells in previous models of human PBMC engraftment suggests a 
strong reactivity against host MHC class I may also be present (131,132,143). 
Furthermore, the high levels of engraftment of both CD4+ and CD8+ human cells 
observed in NOD-scid IL2rγnull mice (177) suggests that reactivity to both host MHC 
class I and class II may occur.  
 To investigate the relative role of murine host MHC class I and class II in human 
cell proliferation, we first stimulated human PBMC in vitro with murine splenocytes 
isolated from mice genetically deficient in each of these molecules. As expected (168), a 
lower precursor frequency of human CD8+ cells was observed following stimulation by 
splenocytes deficient in murine MHC class I, and a lower precursor frequency of human 
CD4+ cells was observed following stimulation by splenocytes deficient in murine MHC 
class II. In vivo, the delay in GVHD observed in human PBMC-engrafted mice lacking 
MHC class I or class II was also consistent with host MHC playing a major role in 
triggering disease development. Comparison of human cell engraftment in these strains 
revealed a decrease in human CD45+ cells in both MHC class I or class II deficient mice 
as compared to as NOD-scid IL2rγnull mice that express both sets of molecules. 
 Surprisingly, however, there was no difference in CD45+ cell engraftment 
between MHC class I and class II deficient recipients even though there was a significant 
  
97 
difference in the kinetics of development of GVHD. This observation suggests that 
human CD45+ cell engraftment is not the only determinant of disease expression, and that 
the engraftment and activation of CD8+ cells appears to have more of a role in mediating 
GVHD than does CD4+ cells. This is also reflected in the ratio of CD4+ to CD8+ cells, 
which was highly skewed towards CD4+ cells in the MHC class I deficient mice that 
exhibited delayed development of GVHD.  
The role of cytokines in GVHD production 
 The role of the inflammatory cytokines, particularly TNFα in GVHD 
pathogenesis has been investigated both in experimental systems and in the clinic. 
Murine studies of GVHD have shown that TNFα has a key role in intestinal damage 
(196-198) and skin manifestations of GVHD (199,200). Clinical data has shown that high 
levels of TNFα production during conditioning regimens prior to allogeneic BMT were 
highly predictive of the subsequent severity of acute GVHD (201-203). Neutralizing the 
TNFα molecules has been shown to decrease pathology in target organs and improve 
survival in murine models of allogeneic GVHD (195,197,198). Similarly, clinical trials in 
which etanercept was used to neutralize serum TNFα in patients with acute GVHD have 
proven this approach efficacious when used in conjunction with methylprednisone 
(183,204). 
 Consistent with published studies (195,197,198), treatment with etanercept, a 
soluble TNFα decoy receptor, was able to delay progression of the GVHD in our model. 
Furthermore, we observed that etanercept mediates its effects in part by reducing the 
engraftment of human CD45+ cells, a sensitive indicator of GVHD.  
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 In agreement with previous studies (175,176), many cytokines, including human 
TNFα, were not detected in plasma samples of PBMC-injected mice. Interestingly, 
plasma levels of human TNFα were higher in etanercept treated compared to untreated 
mice (Figure 18). It is possible that the anti-TNFα antibody binds to an epitope distinct 
from the binding site of the TNF receptor binding site. Because etanercept is a 
recombinant homodimeric TNF receptor, the TNFα mAb used in the detection assay 
would recognize both receptor bound (i.e. etanercept bound), and free human TNFα in 
the plasma. The increase in plasma levels of TNFα over time in the etanercept treated 
mice could be due to TNFα/etanercept complexes that are “trapped” in the vasculature 
prior to clearance. The absence in TNFα in untreated mice could be a result of a 
“cytokine sink” phenomenon (205), in which the cytokine produced is rapidly being 
removed from the circulation by binding to its membrane-bound receptor and is thus not 
detectable in the plasma unless “trapped” by the soluble receptor.  
 In summary, in Chapter 5 we describe a robust model of GVHD disease based on 
the injection of human PBMC into NOD-scid IL2rγnull mice. This model of GVHD 
represents several improvements over that of previously published models. First, this 
model reliably develops GVHD with cell-dose-dependent kinetics. Second, only minimal 
pre-conditioning of the murine host is required. Third, the role of host MHC can now be 
investigated and manipulated to suit the experimental question. Forth, disease progression 
responds to clinical therapeutics in a manner similar to that seen in patients. Finally, the 
ability to non-invasively monitor disease progression by charting weight loss over time 
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makes this model a powerful tool for evaluating future clinical therapeutic interventions 
and understanding underlying mechanisms in human GVHD.  
CONCLUSIONS 
Research goals 
 The long-term goals of our research endeavors are to develop protocols in the 
laboratory that can be used clinically to prolong the survival of allogeneic tissues, and 
decrease the occurrence of GVHD. The development of such protocols in the clinic poses 
many obstacles that must be overcome for success. First, clinical trials of new therapeutic 
agents are an expensive and lengthy undertaking. Second, efficacy trials of new 
therapeutics often start with patients in which current therapies were unsuccessful. As 
this population may prove more resistant to treatment, it will likely be more difficult to 
detect a therapeutic response to the intervention. Third and most important, trials of new 
protocols involve some degree of risk to the patient As such, there are ethical 
considerations to be addressed prior to starting any patient on an untested protocol and a 
careful weighing of the “risk to benefit” for the patient. 
 To minimize patient risk, extensive pre-clinical studies in laboratory animals are 
conducted to predict clinical responses. In the case of immunologic studies, many of 
these pre-clinical studies are carried out in murine models. Unfortunately, studies of 
murine immunity often do not predict outcomes in the clinic (106-108). To overcome this 
limitation, we have developed a murine model of the human alloimmune response based 
on the NOD-scid IL2rγnull strain of immunodeficient mice. 
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A model of human alloimmunity 
 In Chapters 4 and 5, we presented data demonstrating the utility of NOD-scid 
IL2rγnull mice engrafted with human PBMC to model the human alloimmune response. 
We showed that intravenous injection of low doses of human PBMC into NOD-scid 
IL2rγnull mice results in highly reproducible, robust engraftment of human CD45+ cells. 
Further, the engrafted human cells are able to home to and destroy HLA-disparate human 
islets transplanted into the spleen. In the complete absence of host pre-conditioning, there 
is a 30 day “window” of opportunity to study human immunity in the absence of the 
confounding effects of graft-versus-host disease. Building on this observation, we 
modified our model system to develop a robust model of human GVHD by 
preconditioning the mice with 2 Gy total body irradiation prior to injection of human 
PBMC.  
Our data demonstrate that PBMC-engrafted NOD-scid IL2rγnull mice are an 
important model for investigating in vivo mechanisms of human islet allograft rejection 
and GVHD. More importantly, PBMC-engrafted NOD-scid IL2rγnull mice provide a pre-
clinical bridge for evaluating therapies without putting human subjects at risk. 
Mechanisms of human cell engraftment 
 There are several mechanisms that may contribute to the engraftment of human 
PBMC in NOD-scid IL2rγnull mice. Our data show that the primary mechanism of 
engraftment is via the xeno-specific proliferation of human T-cells in response to murine 
MHC. We have shown that a high percentage of human CD4+ cells (~2%) and CD8+ cells 
(~6%) proliferate in vitro in response to murine MHC class II and class I antigens, 
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respectively (Figure 12). The higher precursor frequency of human CD8+ cells compared 
to CD4+ cells in the in vitro mixed lymphocyte reaction assay is consistent with the 
finding that CD8+ T cells predominate in most murine models of human cell engraftment 
(131,132,143). Similarly, the decreased engraftment of human PBMC seen in mice 
deficient at either MHC class I or class II allele supports the hypothesis that host MHC is 
a primary driving force of human PBMC proliferation (Figure 14A). Given the stronger 
stimulus for human cell proliferation by murine MHC class I vs MHC class II, it is 
surprising that mice deficient in either MHC class I or class II engraft with similar levels 
of human CD45+ cells. This could be due in part to a requirement for human CD4+ T cell 
help to support CD8+ T cell engraftment in immunodeficient mice (150). Specifically, 
lower levels of CD4+ engraftment in mice deficient in MHC class II would result in a 
related decrease in CD8+ engraftment, and an overall decrease in the levels of human 
CD45+ cells. In contrast, in the absence of murine MHC class I, there is decreased 
stimulus for the proliferation of human CD8+ cells, resulting in lower levels of CD8+ cell 
engraftment, and a corresponding overall decrease in human CD45+ cell engraftment. 
 Our laboratory has previously reported that NOD-scid β2mnull mice engraft with 
higher levels of CD4+ cells than do NOD-scid mice which was thought to be due to lower 
NK cell activity (140). We now describe the presence of a relatively normal CD4:CD8 
ratio in NOD-scid IL2rγnull mice (Figure 14B). Based on the in vitro data presented in 
Figure 14 in conjunction with differences in overall engraftment of human cells in these 
two strains (Figure 14A), this normal ratio is likely due to the absence of host NK cell 
activity and a relatively equal expansion of each cell population in the host.  
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 There are mechanisms other than recognition of murine MHC that are 
contributing to the human PBMC engraftment in NOD-scid IL2rγnull mice. In vitro 
studies of the proliferative response elicited in human PBMC using murine cells as a 
source of antigen demonstrated that proliferation occurs in the absence of both murine 
MHC class I and class II (Figure 12). This could be due to additional, non-MHC antigens 
evoking a proliferative response from the PBMC. In vivo, an additional mechanism may 
be proliferation as a result of homeostatic expansion (206-208). 
 To determine the mechanism(s) of human cell proliferation in vivo, additional 
phenotyping of the engrafting and proliferating human cells would need to be performed. 
T cells that have undergone homeostatic expansion in vivo acquire a phenotype very 
similar to memory T cells (reviewed in 209). To differentiate between homeostasis-
driven and activation-induced proliferation of human T-cells in this system, antigen-
stimulated T cells have been reported to express the transferrin receptor, CD71, whereas 
T cells expanding by homeostatic mechanisms do not (210). In addition, antigen-driven 
T-cell expansion induces cellular enlargement that is not seen in T cells expanded via 
homeostatic mechanisms (210). Determination of the contribution of homeostatic versus 
antigen-driven proliferation of human T cells in vivo in NOD-scid IL2rγnull mice remains 
an important question. 
 Indirect support for the hypothesis that homeostatic regulation contributes to 
human cell engraftment in NOD-scid IL2rγnull mice is presented in the analysis of the 
kinetics of PBMC engraftment (Figure 3). Human CD45+ cells comprise an increasing 
proportion of total cells recovered from NOD-scid IL2rγnull mice over the first three 
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weeks following PBMC injection. However, after three weeks both the percent (Figure 
3B) and number (Figure 3C) of human CD45+ cells recovered from the spleen reach a 
plateau. This suggests that homeostatic mechanisms for regulating the T-cell 
compartment remain functional even in this xenoreactive system. 
 Finally, in the instance of the islet allorejection model presented in Chapter 4, an 
additional mechanism for engraftment exists. In addition to the human cells that are 
proliferating in response to the murine MHC, there will presumably be a separate and 
distinct population of PBMC that are proliferating in response to the disparate human 
HLA expressed on the transplanted human islets. To date, we have not specifically 
studied the parameters of PBMC engraftment in NOD-scid IL2rγnull mice transplanted 
with human tissues, although this would be an area of great interest.  
 None of the proposed mechanisms for human PBMC engraftment are mutually 
exclusive. The engraftment of PBMC in NOD-scid IL2rγnull mice will most likely involve 
all three mechanisms, with the relative contributions of homeostatic proliferation and 
antigen specific proliferation to antigens other than murine MHC remain to be 
determined. 
Mechanisms of allograft rejection 
 In Chapter 4, we demonstrate that human PBMC injected intravenously into 
NOD-scid IL2rγnull mice are able to home to and destroy allogeneic human islets 
transplanted in the spleen (Figures 6-8). An overwhelming majority of cells that engraft 
in NOD-scid IL2rγnull mice are CD3+ T cells. Other human cell types are present only at 
low levels in the blood and spleen of PBMC engrafted NOD-scid IL2rγnull mice, although 
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an exhaustive search of other tissues has not been performed to date. However, it is most 
probable that the rejection of transplanted human islets by HLA-disparate PBMC is the 
result of targeting by cytotoxic human CD3+ cells. However, it remains to be determined 
whether CD4+ or CD8+ cells in the absence of the other cell subset are able to mediate the 
rejection of allogeneic human tissues in NOD-scid IL2rγnull mice.  
 We recognize that the rejection of human islets in the NOD-scid IL2rγnull mouse 
by allogeneic PBMC occurs in a setting of ongoing xenoreactivity. As the goal of this 
research is to investigate the human alloimmune response and potential targets for 
modulating that response, reducing the xenoreactivity is an important goal of future 
studies. Based on our finding that mice deficient in MHC class I are able to engraft with 
human cells (Figure 14A) while remaining resistant to the development of GVHD 
(Figure 13), it will be particularly interesting to evaluate the ability of PBMC to reject 
allogeneic human islets transplanted into NOD-scid IL2rγnull β2mnull mice.  
Mechanisms of GVHD 
 Because the development of xeno-GVHD is closely linked to the level of 
human cell engraftment (170), the mechanisms underlying the development of GVHD in 
NOD-scid IL2rγnull mice largely mirror the mechanisms of human cell engraftment. For 
instance, consistent with the importance of murine MHC in human PBMC engraftment 
(Figure 14A), mice deficient in either MHC class I or class II have a delayed 
development of GVHD as compared to NOD-scid IL2rγnull mice expressing both MHC 
class I and class II (Figure 13). 
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 The effectiveness of etanercept in preventing GVHD in this model is consistent 
with laboratory (195,197,198) and clinical data (184,204) describing an important role for 
TNFα in the pathogenesis of GVHD. Although the effects of etanercept were clear 
(Figures 15, 16) the mechanism(s) underlying this effect are less clear. One possible 
mechanism is a decrease in human cell engraftment in etanercept-treated mice (Figure 
16B). Another possible mechanism is the reduction of bioavailable human TNFα. 
Interestingly, despite the efficacy of etanercept at ameliorating GVHD in this model, 
human TNFα was not detected in the plasma of PBMC-engrafted mice at any time-point 
tested. In contrast, there were increasing levels of human TNFα detected in the plasma of 
etanercept-treated mice during the 24-hour observation period (Figure 18).  
 Structurally, etanercept is a fusion protein of the dimeric extracellular portion of 
the p75 TNF receptor fused with human IgG1. It is likely that the produced TNFα will 
preferentially form an etanercept/TNFα complex rather than be available for binding to 
cell surface receptors, which would remove TNFα from the circulation. The TNFα bound 
to etanercept would not be bioavailable to the donor PBMC or host cells, leading to 
decreased pathology in etanercept-treated mice. Furthermore, the fusion protein consists 
of the TNFα receptor and IgG1. The immunoglobulin portion of this protein is designed 
to enhance the half-life of the fusion protein in the circulation and effectively permit the 
detection of the produced TNFα. In PBMC recipients that have not been treated with 
etanercept, the absence of detectable levels of TNFα in mice is likely due to a “cytokine 
sink” effect, in which available cytokine is rapidly bound to cell surface receptors and 
utilized by cell populations, and is thus has only a very short half-life in the plasma. 
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Alternatively, it could be that the primary affect of etanercept is due to neutralization of 
murine TNFα. Although our flow based assay was specific for human TNFα, a 
systematic evaluation of murine cytokines and specifically murine TNFα in this model 
system is an important remaining question. 
Remaining limitations 
 While the PBMC-engrafted NOD-scid IL2rγnull mouse model presents many 
advances over its predecessors, there are still limitations to overcome. First, although the 
human PBMC inoculum contains many different populations of leukocyte, the 
predominant cell population to engraft efficiently in NOD-scid IL2rγnull mice is T cells. 
We have hypothesized that the inability of other cell populations, such as B cells, to 
engraft is a function of inefficient cross-reactivity of murine cytokines, growth factors 
and/or survival factors with the human receptors. Efforts are currently underway to 
identify specific factors required for improving engraftment of cell types other than T 
cells.  
 Limitations remain in the use of this model for the study of human alloimmunity 
as well. For example, utilizing human islets as a target of allogeneic PBMC simplifies 
monitoring graft function, as blood glucose levels can easily be monitored. However, 
human islets are not readily available. Those samples that do become available for 
research use have already been passed over for clinical applications, and are of varying 
quality. To circumvent this issue, we are currently investigating the use of islets isolated 
from mice that transgenically express human HLA molecules as targets for human 
alloimmunity. This approach will allow a more detailed investigation into the allo-
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specificity of the rejection response. Experimental questions that need to be addressed 
include whether human PBMC will reject HLA-mismatched (allogeneic) islets while not 
targeting HLA matched (syngeneic) islets  
 Finally, the cost of increased engraftment of human cells in this model is the 
ensuing increase in GVHD. The development of lethal GVHD in PBMC engrafted NOD-
scid IL2rγnull mice beginning about 5 weeks after PBMC injection into unconditioned 
mice limits the timeframe that allograft rejection studies can be done. However, adding 
total body irradiation to the protocol has provided the most robust and reliable model of 
human into mouse xeno-GVHD described to date.  
 Despite these remaining limitations, the utility of PBMC-engrafted NOD-scid 
IL2rγnull mice to model the human alloimmune response remains promising. This model 
system represents a cutting-edge approach to the age-old problem of testing the efficacy 
of clinical therapeutics without putting patients at risk. 
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